PURPOSE AND SCOPE
The purpose of this document is to update key concepts in the management of postpartum
hemorrhage (PPH) and give clear and precise tools to health personnel in low‐ and
middle‐income countries (LMICs) to perform evidence‐based treatments, with the aim
of reducing related maternal morbidity and mortality.
TARGET AUDIENCE
Gynecologists, obstetricians, midwives, nurses, general practitioners, and other health
personnel in charge of the care of pregnant women with PPH.
METHODS
The recommendations were developed as a synthesis and update of evidence from the
literature. They are based on the FIGO Safe Motherhood and Newborn Health Committee
(SMNH) guidelines that were published in 2012
1
and include research and consensus guidelines. For the present document, a bibliographic
review was performed, and studies from LMICs and across regions were identified using
the search engines PubMed, Medline, Embase, Science Direct, and Google Scholar. According
to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach,
this update does not generate a universal level of evidence. However, each section
and the generated conclusions and recommendations use the degrees of evidence that
were identified in the bibliographic review.
Author Contributions
Conceptualization: MFE, AN, GT, EB, WN, DR, IL. Manuscript writing: MFE, AN, GT, TB,
EB, WN, DR, IL, EC, SM, RB, GO, JC, IR, MAI, SL, DN. Review and approval of manuscript:
MFE, AN, GT, EB, WN, DR.
Conflicts of Interest
GT reports a research grant from the South African Medical Research Council to fund
Sinapi Biomedical to develop the Ellavi UBT and conduct associated research. EB reports
part ownership of BioIncept. EC was a member of the Guideline Development Group for
the RCOG’s PPH Greentop Guideline (2016), and the FIGO Guideline on Placenta Acreta
Spectrum (2018). SM reports that Regents, University of California receives a royalty
fee from LifeWrap‐NASG for the use of the trademark name (“LifeWrap”) for a Non‐pneumatic
Anti‐Shock Garment (NASG). TB reports PPH research funded by the Gates Foundation;
PPH Implementation efforts funded by RzHC; PPH Implementation efforts funded by UK
AID; PPH Implementation efforts funded by Grand Challenges Canada; PPH efforts and
research funded by USAID; PPH efforts by Norway Government. Other authors report no
conflicts of interest.
Disclaimer
These FIGO recommendations are not intended to be a sole source of guidance or prescriptive
protocol in managing PPH. They are designed to assist stakeholders by providing an
evidence‐based framework for decision‐making in a PPH setting. The clinical judgment
of the doctor or other practitioner, in the context of the clinical presentation of
the patient and the available resources for diagnosis and treatment, should always
inform the choice of clinical procedure and treatment plan.
Contents
1. Executive summary
7
2. FIGO recommendations for the prevention and treatment of postpartum hemorrhage
8
2.1. FIGO recommendations for prevention of postpartum hemorrhage
8
2.2. FIGO recommendations for treatment of postpartum hemorrhage
8
3. Background
10
3.1. Introduction
10
3.2. Past FIGO recommendations for PPH
10
3.3. Definition of postpartum hemorrhage
10
3.4. Etiologies/risk factors
10
4. Postpartum hemorrhage bundle care
13
5. Shock index evidence in postpartum hemorrhage evaluation and management
15
5.1. Assessment of circulating blood volume in postpartum hemorrhage
15
6. Review of guidelines around the world
17
6.1. Guidelines that address the prevention of
postpartum hemorrhage
17
6.2 Guidelines that address the treatment of
postpartum hemorrhage
20
7. Medical prevention and treatment
27
7.1. Carbetocin versus oxytocin use in PPH: recent evidence
27
7.1.1. Clinical evidence for PPH prevention: oxytocin versus carbetocin (vaginal delivery)
27
7.1.2. Clinical evidence for PPH prevention: oxytocin versus carbetocin (cesarean
delivery)
27
8. Tranexamic acid
30
8.1. Administration of TXA
30
8.2. TXA as a prophylactic measure
30
8.3. Adverse reactions to TXA
31
8.4. Contraindications
31
8.5. Implementation of treatment with TXA
31
9. Nonsurgical conservative management
32
9.1. Nonpneumatic antishock garment (NASG)
32
9.1.1. Safety
32
9.1.2. Effectiveness and advantages
32
9.1.3. Indications
33
9.1.4. Instructions for use
33
9.1.5. Monitoring and removal
33
9.1.6. Adverse effects
34
9.1.7. Contraindications
34
9.2. Uterine balloon tamponade
34
9.2.1. Available UBT devices
35
9.2.2. Tamponade effect
35
9.2.3. Free flow tamponade device
35
9.2.4. Drainage port
35
9.2.5. Correct placement
35
9.2.6. Assessment of effect
35
9.2.7. Transfer
36
9.2.8. UBT after cesarean delivery
36
9.2.9. Combining UBT with compression sutures
36
9.2.10. Other uses of UBT
36
9.3. Uterine artery embolization
37
9.3.1. Complications
38
9.3.2. Implementation of treatment
38
10. Surgical treatment
39
10.1. Uterine compression sutures for PPH
39
10.1.1. Commonly used compression sutures for managing PPH
39
10.2. Uterine artery ligation
40
10.3. Bilateral internal iliac artery ligation
41
10.4. Hysterectomy
41
11. Assessment and resuscitation
43
11.1. Damage control resuscitation in PPH
43
11.1.1. Decision for damage control surgery
43
11.1.2. Bleeding control
43
11.1.2.1. Initial laparotomy
43
11.1.2.2. Resuscitation –ICU
44
11.1.2.3. Definitive surgery
44
11.1.2.4. Definitive closure of abdominal wall and cavity
44
11.1.3. Complications
44
11.1.4. Final objectives in resuscitation
44
11.2. Resuscitation
45
11.2.1. Hypotensive resuscitation
45
11.2.2. Intravenous fluids
45
11.2.3. Targeted blood pressure
45
11.2.4. Aggressive approach and adverse outcomes
45
11.2.5. Evidence
45
11.2.6. Hemostatic resuscitation
46
11.2.7. Transfusion ratios
46
11.2.8. Fibrinogen and cryoprecipitate
46
11.2.9. Massive transfusion protocols
46
11.2.10. Adverse outcomes
47
12. Key statements
48
13. Implementation of the FIGO recommendations by health systems and national societies
for the management of postpartum hemorrhage
50
Members of the FIGO Safe Motherhood and Newborn Health Committee, 2018–2021
50
1
EXECUTIVE SUMMARY
FIGO (International Federation of Gynecology and Obstetrics) is actively contributing
to the global effort to reduce maternal death and disability around the world. Its
mission statement reflects a commitment to promoting health, human rights, and well‐being
of all women, especially those at the most significant risk of death and disability
associated with childbearing. FIGO provides evidence‐based interventions that can
reduce the incidence of maternal morbidity and mortality when applied with informed
consent.
Postpartum hemorrhage (PPH) continues to be the leading cause of maternal morbidity
and mortality in most countries around the world. Despite multiple collaborative efforts
at all levels, there is still a lack of implementation or adherence to the recommendations
for management of PPH when faced with this obstetric emergency. In part, this delay
in implementation lies in the lack of information from current evidence and a lack
of unification of the multiple guidelines for diagnosis and strategies to control
bleeding. To provide clear and practical tools to approach this obstetric emergency,
especially for low‐ and middle‐income countries (LMICs), the FIGO Safe Motherhood
and Newborn Health Committee (SMNH), supported by a group of experts worldwide, developed
this updated review. It aims to provide multiple alternatives for the diagnosis and
management of PPH tailored to the resources available at the institutional, local,
or regional level. This document reflects the best available evidence, drawn from
scientific literature and expert opinion, on the prevention and treatment of PPH in
low‐resource settings. FIGO believes that the greatest impediment in the adoption
of a given strategy is the absence of an effective implementation tool.
2
FIGO RECOMMENDATIONS FOR THE PREVENTION AND TREATMENT OF POSTPARTUM HEMORRHAGE
Health workers at all levels of care (particularly in LMICs) need to have access to
appropriate medications
1
and training in PPH prevention and management procedures. All attempts should be made
to reduce PPH using cost‐effective, resource‐appropriate interventions. At first,
all should be done to avoid PPH and reduce the need for expensive, lifesaving surgical
interventions. The routine use of active management of the third stage of labor by
all attendants, regardless of where they practice, should be recommended.
2
All birth attendants must know how to provide safe care (physiologic management) to
prevent PPH in the absence of uterotonic drugs.
3
2.1
FIGO recommendations for prevention of postpartum hemorrhage
The use of uterotonics for prevention of PPH during the third stage of labor is recommended
for all births.
4
,
5
Oxytocin (10 IU intravenously/intramuscularly [IV/IM]) is recommended for the prevention
of PPH for vaginal delivery and cesarean section.
4
,
5
In settings where oxytocin is used, attention should be paid to the oxytocin cold
chain.
6
In settings where oxytocin is unavailable or its quality cannot be guaranteed, the
use of other injectable uterotonics (if appropriate ergometrine/methylergometrine
200 μg IM/IV; hypertensive disorders can be safely excluded prior to its use) or oral
misoprostol (400–600 µg orally) or carbetocin 100 µg IM/IV is recommended for the
prevention of PPH.
4
,
5
The combinations of ergometrine plus oxytocin or misoprostol plus oxytocin may be
more effective uterotonic drug strategies for the prevention of PPH ≥500 ml compared
with the current standard, oxytocin. This comes at the expense of a higher risk of
adverse effects (vomiting and hypertension with ergometrine and fever with misoprostol).
7
In settings where skilled birth attendants are not present to administer injectable
uterotonics and oxytocin is unavailable, the administration of misoprostol (400–600 μg
orally) by community healthcare workers and lay health workers is recommended for
the prevention of PPH.
4
,
5
In settings where skilled birth attendants are unavailable, controlled cord traction
(CCT) is not recommended.
4
Sustained uterine massage is not recommended as an intervention to prevent PPH in
women who have received prophylactic oxytocin.
8
Postpartum abdominal uterine tonus assessment for early identification of uterine
atony is recommended for all women.
4
Oxytocin (IV or IM) and CCT is the recommended method for removal of the placenta
for the prevention of PPH in cesarean delivery.
4
2.2
FIGO recommendations for treatment of postpartum hemorrhage
Intravenous oxytocin alone is the recommended first‐line uterotonic drug for the treatment
of PPH.
3
,
4
If intravenous oxytocin is unavailable, or if the bleeding does not respond to oxytocin,
the use of intramuscular ergometrine, oxytocin–ergometrine fixed dose, or a prostaglandin
drug (including sublingual misoprostol, 800 μg) is recommended.
3
,
4
,
9
,
10
There is no evidence about the safety and efficacy of an additional 800‐μg dose of
misoprostol for treatment of PPH when given to women who have already received 600 μg
of prophylactic misoprostol orally.
The use of isotonic crystalloids is recommended in preference to the use of colloids
for the initial intravenous fluid resuscitation of women with PPH.
4
,
11
Early use of intravenous tranexamic acid as soon as PPH is diagnosed but within 3 h
of birth in addition to standard care is recommended for women with clinically diagnosed
PPH following vaginal birth or cesarean delivery.
12
,
13
,
14
Administration of 1 g (100 mg/ml) tranexamic acid intravenously at 1 ml/min (i.e.
administered over 10 min), with a second dose of 1 g intravenously if bleeding continues
after 30 min, or if bleeding restarts within 24 h of completing the first dose. Reducing
maternal deaths due to bleeding through scaling up of tranexamic acid for PPH treatment
could have a positive impact on health equity and improve outcomes among disadvantaged
women, especially in LMICs.
15
Uterine massage is recommended for the treatment of PPH.
3
,
4
The use of bimanual uterine compression or external aortic compression for the treatment
of PPH due to uterine atony after vaginal birth is recommended as a temporizing measure
until appropriate care is available.
3
,
4
If women do not respond to treatment using uterotonics, or if uterotonics are unavailable,
the use of uterine balloon tamponade is recommended as an effective nonsurgical technique
that can potentially improve survival in women with PPH due to uterine atony after
ruling out retained products of conception or uterine rupture as a contributing factor.
3
,
4
,
16
Use of the nonpneumatic antishock garment is recommended as a temporizing measure
until appropriate care is available.
3
,
4
The use of uterine packing is not recommended for the treatment of PPH due to uterine
atony after vaginal birth.
3
,
4
Uterine artery embolization can be another conservative management measure for PPH
if technical conditions and skilled human resources are available for its use.
17
If bleeding does not stop despite treatment using uterotonics and other available
conservative interventions (e.g. uterine massage, balloon tamponade), the use of surgical
interventions is recommended.
3
,
4
Surgical interventions include the use of compression suture techniques,
18
uterine and hypogastric artery ligation, and hysterectomy.
The priority is to stop the bleeding before the patient develops coagulation problems
and organ damage from under‐perfusion. Conservative approaches should be tried first,
rapidly moving to more invasive procedures if these do not work.
REFERENCES
1
World Health Organization
. WHO Model List of Essential Medicines. Accessed December 16, 2021. https://www.who.int/groups/expert‐committee‐on‐selection‐and‐use‐of‐essential‐medicines/essential‐medicines‐lists
2
Begley
CM
,
Gyte
GM
,
Devane
D
,
McGuire
W
,
Weeks
A
. Active versus expectant management for women in the third stage of labour. Cochrane
Database Syst Rev. 2011(11):CD007412.22071837
3
Lalonde
A
; International Federation of Gynecology and Obstetrics
. Prevention and treatment of postpartum hemorrhage in low‐resource settings. Int
J Gynecol Obstet. 2012;117:108–118.
4
World Health Organization
. WHO recommendations for the prevention and treatment of postpartum haemorrhage.
Accessed August 11, 2021. https://www.who.int/reproductivehealth/publications/maternal_perinatal_health/9789241548502/en/
5
World Health Organization
. WHO recommendations: Uterotonics for the prevention of postpartum haemorrhage. Accessed
August 11, 2021. https://apps.who.int/iris/bitstream/handle/10665/277276/9789241550420‐eng.pdf?ua=1
6
Oliver
VL
,
Lambert
PA
,
Than
KK
, et al Knowledge, perception and practice towards oxytocin stability and quality:
a qualitative study of stakeholders in three resource limited countries. PLoS One.
2018;13:e0203810.30252860
7
Gallos
I
,
Williams
H
,
Price
M
, et al. Uterotonic drugs to prevent postpartum haemorrhage: a network meta‐analysis.
Health Technol Assess. 2019;23:1–356.
8
Hofmeyr
GJ
,
Abdel‐Aleem
H
,
Abdel‐Aleem
MA
. Uterine massage for preventing postpartum haemorrhage. Cochrane Database Syst Rev.
2013;(7):CD006431.23818022
9
International Federation of Gynecology and Obstetrics
. Be an advocate for better PPH management. Accessed January 7, 2021. https://www.figo.org/news/be‐advocate‐better‐pph‐management
10
Morris
JL
,
Winikoff
B
,
Dabash
R
, et al FIGO's updated recommendations for misoprostol used alone in gynecology and
obstetrics. Int J Gynecol Obstet. 2017;138:363–366.
11
Perel
P
,
Roberts
I
,
Ker
K
. Colloids versus crystalloids for fluid resuscitation in critically ill patients.
Cochrane Database Syst Rev. 2013;(2):CD000567.23450531
12
WOMAN Trial Collaborators
. Effect of early tranexamic acid administration on mortality, hysterectomy, and other
morbidities in women with post‐partum haemorrhage (WOMAN): an international, randomised,
double‐blind, placebo‐controlled trial. Lancet. 2017;389:2105–2116.28456509
13
World Health Organization
. WHO recommendation on tranexamic acid for the treatment of postpartum haemorrhage.
Accessed August 11, 2021. https://www.who.int/reproductivehealth/publications/tranexamic‐acid‐pph‐treatment/en/
14
Shakur
H
,
Beaumont
D
,
Pavord
S
,
Gayet‐Ageron
A
,
Ker
K
,
Mousa
H
. Antifibrinolytic drugs for treating primary postpartum haemorrhage. Cochrane Database
Syst Rev. 2018;(2):CD012964.29462500
15
World Health Organization
. State of Inequality: Reproductive Maternal Newborn and Child Health: Interactive
Visualization of Health Data. Accessed August 11, 2021. https://www.who.int/docs/default‐source/gho‐documents/health‐equity/state‐of‐inequality/state‐of‐inequality‐reproductive‐maternal‐new‐born‐and‐child‐health.pdf?sfvrsn=f4034289_2
16
Tindell
K
,
Garfinkel
R
,
Abu‐Haydar
E
, et al Uterine balloon tamponade for the treatment of postpartum haemorrhage in resource‐poor
settings: a systematic review. BJOG. 2013;120:5–14.22882240
17
Mahankali
SS
. Interventional radiology: a disruptive innovation which is transforming management
of post‐partum haemorrhage. J Obstet Anaesth Crit Care. 2017;7:65–68.
18
Mousa
HA
,
Blum
J
,
Abou El Senoun
G
,
Shakur
H
,
Alfirevic
Z
. Treatment for primary postpartum haemorrhage. Cochrane Database Syst Rev. 2014;(2):CD003249.24523225
3
BACKGROUND
3.1
Introduction
Postpartum hemorrhage (PPH) is an obstetric emergency complicating 1%–10% of all deliveries.
1
It continues to be the leading obstetric cause of maternal death.
1
In 2015, it was reported to be responsible for more than 80 000 maternal deaths worldwide.
1
Its distribution varies across regions, with the highest prevalence of 5.1%–25.7%
reported in Africa, followed by North America at 4.3%–13% and Asia at 1.9%–8%.
2
The incidence of PPH has also been on the rise,
2
,
3
,
4
,
5
increasing from 5.1%–6.2% in Canada between 2003 and 2010,
3
and from 2.9%–3.2% in the USA between 2010 and 2014.
4
3.2
Past FIGO recommendations for PPH
FIGO has made several recommendations in the past 20 years for the management and
treatment of PPH (Table 1). This document will update the recommendations and discuss
new approaches.
TABLE 1
FIGO recommendations on the management of postpartum hemorrhage
FIGO recommendation
Year
References
Management of the third stage of labor to prevent post‐partum hemorrhage
2003
International Confederation of Midwives; International Federation of Gynaecologists
and Obstetricians. Joint statement: management of the third stage of labour to prevent
post‐partum haemorrhage. J Midwifery Womens Health. 2004 Jan‐Feb;49(1):76–7.
Postpartum hemorrhage today: ICM/FIGO initiative 2004–2006
2006
Lalonde A, Daviss BA, Acosta A, Herschderfer K. Int J Gynecol Obstet. 2006;94:243–253.
Prevention and treatment of post‐partum haemorrhage: new advances for low resource
settings
2006
Joint Statement: ICM and FIGO https://www.who.int/pmnch/events/2006/figo2006statementeng.pdf
Prevention and treatment of postpartum hemorrhage in low‐resource settings
2012
Lalonde A; International Federation of Gynecology and Obstetrics. Int J Gynecol Obstet.
2012;117:108–118.
Prevention of postpartum hemorrhage with misoprostol
2012
International Federation of Gynecology and Obstetrics. Int J Gynecol Obstet. 2012;119:213–214.
Treatment of postpartum hemorrhage with misoprostol
2012
International Federation of Gynecology and Obstetrics. Int J Gynecol Obstet. 2012;119:215–216.
Non‐pneumatic anti‐shock garment to stabilize women with hypovolemic shock secondary
to obstetric hemorrhage
2015
FIGO Safe Motherhood and Newborn Health Committee; International Federation of Gynecology
and Obstetrics. Int J Gynecol Obstet. 2015;128:194–195.
FIGO's updated recommendations for misoprostol used alone in gynecology and obstetrics
2017
Morris JL, Winikoff B, Dabash R, et al. Int J Gynecol Obstet. 2017;138:363–366.
Affordable and low‐maintenance obstetric devices
2019
Ayres‐de‐Campos D, Stones W, Theron G; FIGO Safe Motherhood and Newborn Health Committee.
Int J Gynecol Obstet. 2019;146:25–28.
John Wiley & Sons, Ltd
3.3
Definition of postpartum hemorrhage
The lack of consistency in the definition of PPH has been a major limitation to the
ability to compare prevalence in different studies (Table 2). Classically, it was
defined as quantified bleeding of more than 500 ml for vaginal deliveries and more
than 1000 ml for cesarean deliveries, occurring within the first 24 h of delivery.
1
However, this definition did not focus on clinical signs and symptoms of hemorrhage,
and thus prevented early detection in many cases. Therefore, in 2017, the American
College of Obstetricians and Gynecologists (ACOG) changed the definition to blood
loss of more than or equal to 1000 ml, or blood loss that was accompanied by signs
or symptoms of hypovolemia occurring within 24 h after birth, regardless of the mode
of delivery.
6
In contrast, the Royal College of Obstetricians and Gynaecologists (RCOG) defines
PPH according to the volume of blood lost: minor (between 500 and 1000 ml) and major
(>1000 ml).
7
However, the volume of estimated blood loss remains unreliable in many cases, and
therefore much attention should be directed to the general clinical status of the
patient instead.
8
Several tools for assessment of blood loss have been used as accurate estimation will
directly influence the diagnosis and management of PPH. Many groups cite visual estimation
as part of blood loss assessment, but as it has high potential to underestimate hemorrhage,
use of additional tools for more objective estimation, such as gravimetric measurement,
direct blood collection techniques, and evaluation of clinical parameters, have been
proposed.
9
,
10
,
11
,
12
,
13
,
14
,
15
,
16
,
17
Recently, some guidelines have incorporated the shock index
9
,
11
,
14
,
17
and obstetric early warning systems into their recommendations to evaluate bleeding.
11
,
14
,
17
TABLE 2
Summary of postpartum hemorrhage definitions from high‐quality guidelines around the
world
Guideline
Definition
American College of Obstetricians and Gynecologists (2017)
Dutch Society of Obstetrics and Gynecology (2012)
>1000 ml regardless of route of delivery
Any blood loss that causes hemodynamic instability
Federation of Obstetric and Gynaecological Societies of India (2015)
French College of Gynaecologists and Obstetricians/French Society of Anesthesiology
and Intensive Care (2016)
The Royal Australian and New Zealand College of Obstetricians and Gynaecologists (2017)
World Health Organization (2012)
>500 ml regardless of route of delivery
Severe PPH >1000 ml
International Federation of Gynecology and Obstetrics (2012)
Society of Obstetricians and Gynaecologists of Canada (2018)
Vaginal delivery >500 ml, cesarean delivery >1000 ml
Any blood loss that has the potential to produce hemodynamic instability
Royal College of Obstetricians and Gynaecologists (2016)
>500 ml regardless of the route of delivery
PPH mild: 500–1000 ml, moderate: 1000–2000 ml, severe: >2000 ml
German Society of Gynecology and Obstetrics/Austrian Society of Obstetrics and Gynecology/Swiss
Society of Gynaecology and Obstetrics (2018)
Vaginal delivery ≥500 ml or cesarean delivery ≥1000 ml
John Wiley & Sons, Ltd
3.4
Etiologies/risk factors
While there exist several identifiable risk factors for PPH, most cases occur unexpectedly.
6
,
18
An easy way to remember the most common etiologies is to remember the four T’s
19
:
Tone: uterine atony (accounts for 70% of PPH cases).
20
Trauma: genital tract trauma.
Tissue: retained products of conception.
Thrombin: coagulopathy.
Uterine atony can be anticipated after prolonged labor particularly with the use of
oxytocin, in pregnancies complicated with chorioamnionitis, high parity, general anesthesia,
and other factors that lead to uterine overdistension such as multiple fetal gestation,
polyhydramnios, and fetal macrosomia.
6
,
20
Trauma accounts for 15%–20% of cases,
21
and is mostly attributed to perineal or cervical lacerations, perineal hematomas,
episiotomies, or uterine rupture.
6
,
20
These occur in the setting of precipitous uncontrolled deliveries or operative vaginal
deliveries.
6
Retained products of conception can increase the risk of PPH by 3.5 times.
22
Risk factors include succenturiate placenta and previous instrumentation.
6
Coagulation problems can be divided into inherited, such as von Willebrand diseases,
hemophilia, and idiopathic thrombocytopenic purpura, and acquired, such as the use
of anticoagulant therapy
20
and the occurrence of disseminated intravascular coagulopathy after placental abruption,
pre‐eclampsia with severe features, intrauterine fetal demise, sepsis, or amniotic
fluid embolism.
6
,
20
,
23
Other etiologies include uterine inversion and abnormal placentation.
REFERENCES
1
Borovac‐Pinheiro
A
,
Pacagnella
RC
,
Cecatti
JG
, et al Postpartum hemorrhage: new insights for definition and diagnosis. Am J Obstet
Gynecol. 2018;219:162–168.29660298
2
Calvert
C
,
Thomas
SL
,
Ronsmans
C
,
Wagner
KS
,
Adler
AJ
,
Filippi
V
. Identifying regional variation in the prevalence of postpartum haemorrhage: a systematic
review and meta‐analysis. PLoS One. 2012;7:e41114.22844432
3
Mehrabadi
A
,
Liu
S
,
Bartholomew
S
, et al Temporal trends in postpartum hemorrhage and severe postpartum hemorrhage
in Canada from 2003 to 2010. J Obstet Gynaecol Can. 2014;36:21–33.24444284
4
Reale
SC
,
Easter
SR
,
Xu
X
,
Bateman
BT
,
Farber
MK
. Trends in Postpartum Hemorrhage in the United States From 2010 to 2014. Anesth Analg.
2020;130:e119–e122.31567319
5
Carroli
G
,
Cuesta
C
,
Abalos
E
,
Gulmezoglu
AM
. Epidemiology of postpartum haemorrhage: a systematic review. Best Pract Res Clin
Obstet Gynaecol. 2008;22:999–1012.18819848
6
Committee on Practice Bulletins‐Obstetrics
. Practice bulletin no. 183: postpartum hemorrhage. Obstet Gynecol. 2017;130:e168–e186.28937571
7
Prevention and management of postpartum haemorrhage: green‐top guideline no. 52. BJOG.
2017;124:e106–e149.27981719
8
Dahlke
JD
,
Mendez‐Figueroa
H
,
Maggio
L
, et al Prevention and management of postpartum hemorrhage: a comparison of 4 national
guidelines. Am J Obstet Gynecol. 2015;213:76.e1–76.e10.25731692
9
Pan American Health Organization
. Guidelines for the prevention, diagnosis and treatment of obstetric hemorrhage [in
Portuguese]. PAHO; 2018.
10
Leduc
D
,
Senikas
V
,
Lalonde
AB
. No. 235‐active management of the third stage of labour: prevention and treatment
of postpartum hemorrhage. J Obstet Gynaecol Can. 2018;40:e841–e855.30527079
11
Mavrides
E
,
Allard
S
,
Chandraharan
E
, et al.; on behalf of the Royal College of Obstetricians and Gynaecologists
. Prevention and management of postpartum haemorrhage. BJOG. 2016;124:e106–e149.27981719
12
Sentilhes
L
,
Vayssière
C
,
Deneux‐Tharaux
C
, et al Postpartum hemorrhage: guidelines for clinical practice from the French College
of Gynaecologists and Obstetricians (CNGOF): in collaboration with the French Society
of Anesthesiology and Intensive Care (SFAR). Eur J Obstet Gynecol Reprod Biol. 2016;198:12–21.26773243
13
Royal Australian and New Zealand College of Obstetricians and Gynaecologists
. RANZCOG statement. Management of postpartum hemorrhage. Accessed August 11, 2021.
https://ranzcog.edu.au/RANZCOG_SITE/media/RANZCOG‐MEDIA/Women%27s%20Health/Statement%20and%20guidelines/Clinical‐Obstetrics/Management‐of‐Postpartum‐Haemorrhage‐(C‐Obs‐43)‐Review‐July‐2017.pdf?ext=.pdf
14
Sri Lanka College of Obstetrician and Gynecologists
. SLCOG Guideline on Management of Primary PostPartum Haemorrhage. Accessed August
11, 2021. https://www.slcog.lk/wp‐content/uploads/2021/02/SLCOG‐Guideline‐on‐Management‐of‐Primary‐Post‐Partum‐Haemorrhage‐03.‐2020.pdf
15
Shields
LE
,
Goffman
D
,
Caughey
A
; Committee on Practice Bulletins—Obstetrics
. ACOG practice bulletin: Clinical management guidelines for obstetrician‐gynecologists.
Obstet Gynecol. 2017;130(4):e168–e186.28937571
16
Schlembach
D
,
Helmer
H
,
Henrich
W
, et al. Peripartum haemorrhage, diagnosis and therapy. Guideline of the DGGG, OEGGG
and SGGG (S2k Level, AWMF Registry No. 015/063, March 2016). Geburtshilfe Frauenheilkd.
2018;78:382–399.29720744
17
Fawcus
S
. Alerts for managing postpartum haemorrhage. S Afr Med J. 2018;108:1013–1017.
18
Newsome
J
,
Martin
JG
,
Bercu
Z
,
Shah
J
,
Shekhani
H
,
Peters
G
. Postpartum hemorrhage. Tech Vasc Interv Radiol. 2017;20:266–273.29224660
19
Anderson
J
,
Etches
D
. Prevention and management of postpartum hemorrhage. Am Fam Physician. 2007;75:875–882.17390600
20
Oyelese
Y
,
Anant
CV
. Postpartum hemorrhage: epidemiology, risk factors, and causes. Clin Obstet Gynecol.
2010;53:147–156.20142652
21
Sentilhes
L
,
Merlot
B
,
Madar
H
,
Sztark
F
,
Brun
S
,
Deneux‐Tharaux
C
. Postpartum haemorrhage: prevention and treatment. Expert Rev Hematol. 2016;9:1043–1061.27701915
22
Sheiner
E
,
Sarid
L
,
Levy
A
,
Seidman
DS
,
Hallak
M
. Obstetric risk factors and outcome of pregnancies complicated with early postpartum
hemorrhage: a population‐based study. J Matern Fetal Neonatal Med. 2005;18:149–154.16272036
23
Evensen
A
,
Anderson
JM
,
Fontaine
P
. Postpartum hemorrhage: prevention and treatment. Am Fam Physician. 2017;95:442–449.28409600
4
POSTPARTUM HEMORRHAGE BUNDLE CARE
Multimodal strategies have been implemented in high‐income countries to control pathologies
with high mortality rates such as PPH. These initiatives that involve multiple intervention
points and actors have been called “bundles” or intervention packages, which consist
of the implementation of a group of interventions as well as multidisciplinary programs
that standardize and comprehensively address the management of pathologies.
1
,
2
,
3
,
4
,
5
,
6
Bundles represent a selection of existing guidelines and recommendations in a form
that aids systematic implementation and a consistency of practice.
The California Maternal Quality Care Collaborative (CMQCC) Working Group on obstetrical
hemorrhage developed the Improving the Health Care Response to Obstetric Bleeding
Toolkit in 2010 to help obstetric providers, clinical staff, hospitals, and healthcare
organizations develop methods within their facility for timely recognition and an
organized and rapid response to bleeding. In March 2015, version 2.0 was updated with
the latest evidence‐based changes.
6
In 2015, work groups of the National Partnership for Maternal Safety — within the
Council on Patient Safety in Women's Health Care that represents all major women's
healthcare professional organizations in the USA — developed an obstetric hemorrhage
safety bundle. The goal of the partnership was the adoption of the safety bundle by
every birthing facility. This consensus bundle is organized into four action domains:
readiness; recognition and prevention; response; and reporting and systems learning.
There are 13 key elements within these four action domains (Table 3).
TABLE 3
Obstetric hemorrhage safety bundle action domains from the National Partnership for
Maternal Safety, Council on Patient Safety in Women's Health
a
Domain
Key elements
Readiness (Every Unit)
Hemorrhage cart with supplies, checklist, and instruction cards for uterine balloon
tamponade and compression sutures.
Immediate access to hemorrhage medications (kit or equivalent).
A response team to call when help is needed (blood bank, advanced gynecologic surgery,
other support and tertiary services).
Massive and emergency‐release transfusion protocols (type‐O negative or uncross‐matched).
Unit education on protocols, unit‐based drills (with post drill debriefs).
Recognition and Prevention (Every Patient)
Assessment of hemorrhage risk (prenatal, on admission, and at other appropriate times).
Measurement of cumulative blood loss (formal and as quantitative as possible).
Active management of the third stage of labor (department‐ wide protocol).
Response (Every Hemorrhage)
Uni‐standard, stage‐based obstetric hemorrhage emergency management plan with checklists.
Support program for patients, families, and staff for all significant hemorrhages.
Reporting and Systems Learning (Every Unit)
Establish a culture of huddles for high‐risk patients and post‐event debriefs to identify
successes and opportunities.
Multidisciplinary review of serious hemorrhages for systems issues.
Outcomes monitoring and process metrics in perinatal quality improvement committee.
a
Reproduced from Council on Patient Safety in Women's Health Care.
7
© 2015 American College of Obstetricians and Gynecologists. Reproduced with kind permission.
John Wiley & Sons, Ltd
In 2017, the World Health Organization (WHO) carried out a technical consultation
among international maternal health experts to evaluate the development of care bundles
for PPH. A total of 730 articles were reviewed and 430 were used for the construction
of the theoretical framework of the process. The consultation led to a definition
of two care bundles, which are summarized in Table 4.
TABLE 4
Final care bundles for postpartum hemorrhage
a
PPH care bundle
Components
First response PPH bundle
Uterotonic drugs
Isotonic crystalloids
Tranexamic acid
Uterine massage
Notes: Initial fluid resuscitation is performed together with intravenous (IV) administration
of uterotonics. If IV uterotonics are not available, fluid resuscitation should be
started in parallel with sublingual misoprostol or other parenteral uterotonics. If
PPH is in the context of placental retention, the placenta should be extracted, and
a single dose of antibiotics should be administered. If lacerations are encountered,
they should be repaired.
Response to refractory PPH bundle
Compressive measures (aortic compression or bimanual uterine compression)
Intrauterine balloon tamponade
Non‐pneumatic antishock garment
Notes: A continuing dose of uterotonics (e.g. oxytocin diluted in isotonic crystalloids)
and a second dose of tranexamic acid should be administered during the application
of this bundle.
a
Reproduced from Althabe et al.
8
John Wiley & Sons, Ltd
The first response PPH bundle must be implemented at both the primary healthcare and
hospital levels. The discussion about the response to refractory PPH bundle raised
some controversy. For the first response PPH bundle, the next phase is the development
of an implementation strategy, culminating in a model for use at the facility level
in LMICs. For the response to refractory PPH bundle, it is a priority to solve pending
controversies, including the operational definition of refractory PPH, and to better
understand the effectiveness of various uterine balloon tamponade (UBT) devices.
BOX 1
FIGO recommends incorporation of the PPH bundle approach in the management of PPH.
FIGO considers that the bundle care approach can improve patient outcomes when adherence
to all components is high. Every health system needs to adopt a bundle and there are
many available for use. Place the bundle in every maternity hospital and train to
all elements of bundle, from arrival on obstetrics service to transfer to higher level
of care.
REFERENCES
1
Einerson
BD
,
Miller
ES
,
Grobman
WA
. Does a postpartum hemorrhage patient safety program result in sustained changes
in management and outcomes?
Am J Obstet Gynecol. 2015;212:140–144.25019484
2
Shields
LE
,
Wiesner
S
,
Fulton
J
,
Pelletreau
B
. Comprehensive maternal hemorrhage protocols reduce the use of blood products and
improve patient safety. Am J Obstet Gynecol. 2015;212:272–280.25025944
3
Council on Patient Safety in Women's Health Care
. Maternal safety. Accessed August 25, 2021. https://safehealthcareforeverywoman.org/council/patient‐safety‐bundles/maternal‐safety‐bundles/
4
Institute for Healthcare Improvement
. Evidence‐based care bundles. Accessed November 15, 2020. http://www.ihi.org/Topics/Bundles/Pages/default.aspx
5
Main
EK
,
Goffman
D
,
Scavone
BM
, et al National partnership for maternal safety: consensus bundle on obstetric hemorrhage.
Obstet Gynecol. 2015;126:155–162.26241269
6
California Maternal Quality Care Collaborative Improving Health Care Response to Obstetric
Hemorrhage. Accessed November 8, 2021. https://www.cmqcc.org/resources‐tool‐kits/toolkits/ob‐hemorrhage‐toolkit
7
Council on Patient Safety in Women's Health Care
. Patient safety bundle: Obstetric hemorrhage. Accessed January 7, 2022. https://safehealthcareforeverywoman.org/wp‐content/uploads/safe‐health‐care‐for‐every‐woman‐Obstetric‐Hemorrhage‐Bundle.pdf
8
Althabe
F
,
Therrien
MNS
,
Pingray
V
, et al. Postpartum hemorrhage care bundles to improve adherence to guidelines: a
WHO technical consultation. Int J Gynecol Obstet. 2020;148:290–299.
5
SHOCK INDEX EVIDENCE IN POSTPARTUM HEMORRHAGE EVALUATION AND MANAGEMENT
Shock refers to a reduction in tissue perfusion, which is insufficient to meet the
metabolic requirements of tissues and organs. Insufficient blood flow may be clinically
identified as the development of one or more of the following: lactic acidosis, altered
mental status, oliguria, and tachycardia. Vital signs monitoring is key to hemodynamic
assessment and prompt intervention.
1
In healthy pregnant and postpartum women, cardiologic physiologic compensatory mechanisms
prevent changes in vital signs until a large volume of blood has been lost (usually
>1000 ml). Hence, changes in clinical and vital signs that result from hemorrhage
appear late in the process and may not lead to early identification of PPH. This in
turn makes it difficult to establish cutoff points to trigger clinical interventions.
Moreover, because traditional vital signs change late and are less reliable as triggers
for clinical actions, other indicators could help to characterize maternal hypovolemia
caused by bleeding.
2
Although the use of conventional individual vital signs (pulse and systolic blood
pressure) may lack accuracy in the assessment of hypotension, a simple combination
of both may transform routine clinical parameters into a more accurate indicator of
hypovolemia, such as the shock index (SI). SI is defined as the ratio of heart rate
to systolic blood pressure.
3
,
4
The SI may improve the predictive capability of individual clinical signs, which aids
early identification of women at risk of hypovolemia as the result of obstetric causes.
5
Moreover, the SI has been proposed as a reliable indicator of adverse maternal outcomes,
6
and its values have been set to indicate clinical management.
7
However, the association between shock parameters and advanced treatment modalities
in severe PPH has yet to be reported.
5.1
Assessment of circulating blood volume in postpartum hemorrhage
The essential cornerstone of management of PPH involves prompt diagnosis and rapid
replacement of lost blood volume, as well as the oxygen‐carrying capacity of blood,
accompanied by immediate medical and surgical measures to address the underlying cause(s),
and hence prevent more loss. To assess the patient's condition, SI has been introduced
as a simple and clinically effective vital sign.
The SI has been shown to have an inverse linear relationship with left ventricular
stroke work in acute circulatory failure. Therefore, a concurrent reduction of left
ventricular stroke work (induced by hemorrhage, trauma, or sepsis) was associated
with an elevation of the SI and a deterioration in left ventricular mechanical performance.
Poor left ventricular function or persistent abnormal elevation of the SI after aggressive
therapy and hemodynamic stabilization was associated with increased mortality in critically
ill, traumatized patients.
8
In obstetric and nonobstetric circumstances, the absence of a significant drop in
blood pressure in patients with PPH may mask the actual hypovolemic status due to
physiological compensatory mechanisms.
9
For that reason, the SI was the only promising marker that indicated the severity
of blood loss.
2
,
5
The SI, together with the rule of 30, are important tools that may aid clinicians
in an emergency to determine the amount of blood loss and the degree of hemodynamic
instability. Before the fall in systolic blood pressure, heart rate rises to compensate
for the blood loss, and thus the SI increases. The rule of 30 is an approximated blood
loss of 30% of normal (70 ml/kg in adults, 100 ml/kg throughout pregnancy), defined
by a fall of 30% in hematocrit, a fall of 30% in hemoglobin (approximately 3 g/dl),
a fall of 30 mm Hg in systolic blood pressure, and a rise in pulse rate by 30 beats
per minute.
10
It has been shown that an SI ≥0.9 is associated with increased mortality and an SI>1
increases the likelihood of blood transfusion.
11
,
12
To date, standard obstetric SI has been defined as 0.7–0.9 compared with 0.5–0.7 for
the nonpregnant population, taking into account that the hemodynamic changes of pregnancy
may delay the recognition of hypovolemia.
5
If intravascular volume depletion is suspected, a rapid clinical assessment is required
because the patient's clinical condition can deteriorate, leading to the development
of hemorrhagic shock rapidly. Proper medical record‐taking skills may highlight symptoms
associated with shock such as pain and overt blood loss, as well as general malaise,
anxiety, and dyspnea. Notably, in settings where few PPH treatment options exist,
and in cases of home deliveries, diagnosis and treatment or referral must occur even
earlier than in hospital settings to improve outcomes. For that reason, SI may be
a valuable threshold in LMICs, where mortality is highest and is often related to
delays in complication recognition, transportation, and level of care at the facility.
2
A threshold of SI ≥0.9 should be tested to alert community healthcare providers of
the need for urgent transfer.,
13
BOX 2
FIGO recommends use of the shock index in the diagnosis and management of PPH.
FIGO considers that the shock index can be a marker of the severity of PPH and can
alert teams to hemodynamic instability when its value is greater than 0.9.
REFERENCES
1
Schorn
MN
. Measurement of blood loss: review of the literature. J Midwifery Womens Health.
2010;55:20–27.20129226
2
Borovac‐Pinheiro
A
,
Pacagnella
RC
,
Cecatti
JG
, et al Postpartum hemorrhage: new insights for definition and diagnosis. Am J Obstet
Gynecol. 2018;219:162–168.29660298
3
Arulkumaran
S
,
Karoshi
M
,
Keith
LG
,
Lalonde
AB
,
B‐Lynch
C
. A comprehensive textbook of postpartum hemorrhage: an essential clinical reference
for effective management. Sapiens Publishing; 2012.
4
Rady
MY
,
Nightingale
P
,
Little
RA
,
Edwards
JD
. Shock index: a re‐evaluation in acute circulatory failure. Resuscitation. 1992;23:227–234.1321482
5
Pacagnella
RC
,
Souza
JP
,
Durocher
J
, et al A systematic review of the relationship between blood loss and clinical signs.
PLoS One. 2013;8:e57594.23483915
6
El Ayadi
AM
,
Nathan
HL
,
Seed
PT
, et al Vital sign prediction of adverse maternal outcomes in women with hypovolemic
shock: the role of shock index. PLoS One. 2016;11:e0148729.26901161
7
Le Bas
A
,
Chandraharan
E
,
Addei
A
,
Arulkumaran
S
. Use of the “obstetric shock index” as an adjunct in identifying significant blood
loss in patients with massive postpartum hemorrhage. Int J Gynecol Obstet. 2014;124:253–255.
8
Rady
MY
,
Smithline
HA
,
Blake
H
,
Nowak
R
,
Rivers
E
. A comparison of the shock index and conventional vital signs to identify acute,
critical illness in the emergency department. Ann Emerg Med. 1994;24:685–690.8092595
9
Troiano
NH
,
Witcher
PM
,
Baird
SM
. High‐Risk & Critical Care Obstetrics. Lippincott Williams & Wilkins; 2018.
10
Chandraharan
E
,
Arulkumaran
S
. Obstetric and Intrapartum Emergencies: A Practical Guide to Management. Cambridge
University Press; 2012.
11
Vandromme
MJ
,
Griffin
RL
,
Kerby
JD
,
McGwin
G
Jr
,
Rue
LW
3rd
,
Weinberg
JA
. Identifying risk for massive transfusion in the relatively normotensive patient:
utility of the prehospital shock index. J Trauma. 2011;70(2):384–390; discussion 388–90.21307738
12
Cannon
CM
,
Braxton
CC
,
Kling‐Smith
M
,
Mahnken
JD
,
Carlton
E
,
Moncure
M
. Utility of the shock index in predicting mortality in traumatically injured patients.
J Trauma. 2009;67:1426–1430.20009697
13
Nathan
HL
,
El Ayadi
A
,
Hezelgrave
NL
, et al Shock index: an effective predictor of outcome in postpartum haemorrhage?
BJOG. 2015;122:268–275.25546050
6
REVIEW OF GUIDELINES AROUND THE WORLD
Guidelines are defined as systematically developed statements that assist practitioners
to take decisions about appropriate health care in specific clinical circumstances.
1
Over the past decades, many national and international PPH guidelines have been developed
and become part of obstetric clinical practice around the world. PPH guidelines usually
address similar topics (e.g. diagnosis, prevention, and treatment of PPH) but may
differ in their recommendations.
2
,
3
,
4
These differences are because most of the recommendations are based on observational
studies, clinical judgment, and expert opinion. There are few randomized controlled
trials available to produce strong recommendations for the management of PPH due to
the emergency of the condition that hinders this type of study. In the absence of
randomized trials, guidelines gather the best available evidence. In addition, population
characteristics, cultural aspects, resources availability, as well as frequency and
timing of updates may influence the guidelines’ contents and justify some disparities.
1
,
2
,
3
,
4
REFERENCES
1
Woolf
SH
,
Grol
R
,
Hutchinson
A
,
Eccles
M
,
Grimshaw
J
. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines.
BMJ. 1999;318:527–530.10024268
2
Sentilhes
L
,
Goffinet
F
,
Vayssière
C
,
Deneux‐Tharaux
C
. Comparison of postpartum haemorrhage guidelines: discrepancies underline our lack
of knowledge. BJOG. 2017;124:718–722.27699997
3
Bohlmann
MK
,
Rath
W
. Medical prevention and treatment of postpartum hemorrhage: a comparison of different
guidelines. Arch Gynecol Obstet. 2014;289:555–567.24006033
4
Dahlke
JD
,
Mendez‐Figueroa
H
,
Maggio
L
, et al Prevention and management of postpartum hemorrhage: a comparison of 4 national
guidelines. Am J Obstet Gynecol. 2015;213(1):76.e1–76.e10.25731692
6.1
Guidelines that address the prevention of postpartum hemorrhage
Active management of third stage of labor is frequently discussed in guidelines.
1
,
2
,
3
,
4
,
5
,
6
,
7
There is consensus that all women should receive uterotonics after delivery as it
has proven to reduce PPH rates. Oxytocin has been cited as the drug of choice by most
guidelines, but its dosages and route of administration vary largely, especially when
considering mode of delivery.
1
,
2
,
3
,
4
,
5
,
7
,
8
,
9
,
10
In 2012, FIGO established recommendations for the prevention of PPH
11
and in 2018 WHO updated its recommendation for pharmacological PPH prevention and
reinforced the use of oxytocin (10 IU intramuscularly or intravenously) as the drug
of choice.
12
WHO also recommends the use of carbetocin (if cost‐effective), ergot alkaloids (alone
or combined if there are no contraindications), or oral misoprostol in settings where
oxytocin is not available or its quality cannot be guaranteed. Misoprostol is also
recommended when the use of other injectable uterotonics is not possible due to unavailability
or contraindication to use such as hypertension in the context of ergometrine.
12
,
13
The Society of Obstetricians and Gynaecologists of Canada (SOGC) has updated its publication
and reinforced the use of carbetocin as a first‐line uterotonic for prevention at
cesarean delivery or vaginal delivery with one risk factor.
6
The German/Austrian/Swiss guideline mentions that prophylaxis during cesarean delivery
can consist of administering either oxytocin or carbetocin.
5
Other prophylactic strategies have been proposed in guidelines, but many had no great
consensus or no clear benefits.
1
,
2
,
3
,
4
,
5
,
6
,
7
Table 5 summarizes various PPH prevention strategies described by different societies
worldwide.
TABLE 5
Summary of postpartum hemorrhage prevention strategies from high‐quality guidelines
around the world
Guideline/year of publication
Active management of third stage of labor
Pharmacological prevention
Other considerations
1st line uterotonic
Oxytocin
Alkaloid ergot
Misoprostol
Carbetocin
TXA
FIGO 2012
Recommended:
Administration of uterotonics after delivery
Oxytocin
10 IU/ml IM or 5 IU slow IV push within the first minute after delivery
Ergometrine or methylergometrine 0.2 mg IM, if oxytocin is not available or cannot
be safety used
600 μg orally within the first minute after delivery, if oxytocin is not available
or cannot be safety used
Not mentioned
Not mentioned
Controlled cord traction (only when a skilled attendant is present at delivery), uterine
massage after delivery
FOGSI 2015
Recommended:
Uterotonic agent at the time of birth, late cord clamp and controlled cord traction
Oxytocin
Mentioned 10–40 IU; IV or IM or umbilical cord vein, IMM or intramyometrial
If oxytocin is not available: Ergometrine 0.25 mg IM or IMM
400–600 μg (oral, per rectum, per vagina or rectal route) can be used if injectable
uterotonics are not available
Not mentioned
Not mentioned
Nipple stimulation or early breast feeding
RCOG 2016
Recommended:
Routine administration of uterotonics after delivery
Oxytocin
Vaginal birth: 10 IU IM
Cesarean: 5 IU IV, slowly
Ergometrine–oxytocin may be used in the absence of hypertension.
Does not mention dosages
Mentioned, without dosage recommendations
Mentioned, without dosage recommendations
Consider TXA: 0.5–1.0 g IV, plus oxytocin, at cesarean in women at increased risk
Prefer deferred cord clamping (RCOG 2015)
Uterine massage is of no benefit for prevention
CNGOF/SFAR 2016
Recommended:
Administration of uterotonics after delivery
Oxytocin
5 or 10 IU IM or IV slow
At cesarean: Routine maintenance can be performed as long as it does not exceed 10 IU/h
Not mentioned
Not mentioned
Mentioned (in the absence of a no inferiority trial, oxytocin remains the reference
for preventing PPH after cesarean deliveries)
TXA must not be used routinely for PPH prevention
Routine cord drainage, controlled cord traction, uterine massage, routine voiding
after delivery, early or late cord clamping, breastfeeding and any particular position
are not recommended for PPH prevention
ACOG 2017
Recommended:
Routine administration of uterotonics after delivery
Oxytocin
Mentioned 10 IU IV or IM
Mentioned in association with oxytocin, but did not discuss dosages and their sole
use
Not mentioned
Data is insufficient to recommend it
Nipple stimulation or breastfeeding has no effect on prevention.
Prefer delayed cord clamping (ACOG 2017–2)
RANZCOG 2017
Recommended:
Uterotonics and assisted placenta delivery
Oxytocin
Recommended, but do not mention dosages
Not mentioned
Used when oxytocin is not available. Does not discuss dosages
Not mentioned
Not mentioned
Identify risk factors. Determine placental location by antenatal ultrasound
WHO 2018*
Recommended:
Oxytocin
10 IU IM or IV for all births
In settings where oxytocin is unavailable, or its quality is not guaranteed: ergots
alone or associated; or misoprostol; or carbetocin can be used
Not mentioned
Injectable prostaglandins are not recommended
*(Supersedes previous 2012 WHO guideline recommendations of uterotonics for the prevention
of PHH)
WHO guideline (2012): Uterotonics, late cord clamp and controlled cord traction if
skilled attendant
Regardless of route of delivery
Ergometrine or M‐Ergometrine: 0.2 mg IM or IV or Combination: oxytocin 5 IU+Ergometrine
0.5 mg IM (after hypertension is excluded prior to its use)
Misoprostol 400 μg or 600 μg, orally.
If injectable uterotonics are not feasible
Carbetocin: 100 μg IM or IV.
Where its cost is comparable to other effective uterotonics
Recommended for the prevention of PPH. (Carboprost or sulprostone)
SOGC 2018
Recommended: Uterotonics, late cord clamp and controlled cord traction
Vaginal low risk: Oxytocin
Cesarean:
Carbetocin
Vaginal: 10 IU IM or oxytocin, 20–40 IU in 1000 ml, 150 ml per hour.
Ergonovine, 0.2 mg IM
When oxytocin is not available
600–800 μg (oral, sublingual, or rectal route)
When oxytocin is not available
Carbetocin, 100 μg given as an IV bolus over 1 min
Not mentioned
Suggest considering carbetocin for high‐risk women delivering vaginally
DGGG/OEGGG/SSGO 2018
Recommended: Oxytocin after birth
Vaginal: Oxytocin
Cesarean: Oxytocin or carbetocin
3–5 IU slow IV
Not mentioned
Not mentioned
100 µg by short infusion or slow IV infusion
Not mentioned
Immediate cord clamping and controlled cord traction have no impact on reducing PPH
and should not be carried out
FLASOG 2018
Recommended
Oxytocin
10 IU IM or IV
Not mentioned
600 ug oral when oxytocin is not available
Not Mentioned
Not mentioned
Controlled cord traction, (only when a skilled attendant is present at delivery),
uterine massage after delivery
Abbreviations: TXA, tranexamic acid; FIGO, International Federation of Gynecology
and Obstetrics; IU, international unit; IM, intramuscular; IV, intravenous; FOGSI,
Federation of Obstetric and Gynaecological Societies of India; IMM, intramammary;
RCOG, Royal College of Obstetricians and Gynaecologists; CNGOF/SFAR, College of Gynaecologists
and Obstetricians/French Society of Anesthesiology and Intensive Care; ACOG, American
College of Obstetricians and Gynecologists; RANZCOG, Royal Australian and New Zealand
College of Obstetricians and Gynaecologists; WHO, World Health Organization; SOGC,
Society of Obstetricians and Gynaecologists of Canada; DGGG/OEGGG/SSGO, German Society
of Gynecology and Obstetrics/Austrian Society of Obstetrics and Gynecology/Swiss Society
of Gynaecology and Obstetrics, FLASOG, Federación Latinoamericana de Sociedades de
Obstetricia y Ginecología.
John Wiley & Sons, Ltd
BOX 3
FIGO recommends use of oxytocin (10 IM/IV) for prevention of PPH for all births as
a first‐line uterotonic agent.
If oxytocin is not available or its quality is in doubt, other options include carbetocin,
misoprostol, or ergot alkaloids.
Controlled cord traction is recommended for vaginal births in settings where skilled
birth attendants are available.
Early cord clamping (<1 min after birth) is not recommended unless the neonate needs
immediate resuscitation.
Postpartum assessment of uterine tonus is recommended for all women.
REFERENCES
1
Prevention and management of postpartum haemorrhage: green‐top guideline no. 52. BJOG.
2017;124:e106–e149.27981719
2
Sentilhes
L
,
Vayssière
C
,
Deneux‐Tharaux
C
, et al Postpartum hemorrhage: guidelines for clinical practice from the French College
of Gynaecologists and Obstetricians (CNGOF): in collaboration with the French Society
of Anesthesiology and Intensive Care (SFAR). Eur J Obstet Gynecol Reprod Biol. 2016;198:12–21.26773243
3
World Health Organization
. WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage.
Accessed August 11, 2021. https://www.who.int/reproductivehealth/publications/maternal_perinatal_health/9789241548502/en/
4
Committee on Practice Bulletins‐Obstetrics
. Practice bulletin no. 183: postpartum hemorrhage. Obstet Gynecol. 2017;130:e168–e186.28937571
5
Schlembach
D
,
Helmer
H
,
Henrich
W
, et al. Peripartum haemorrhage, diagnosis and therapy. Guideline of the DGGG, OEGGG
and SGGG (S2k Level, AWMF Registry No. 015/063, March 2016). Geburtshilfe Frauenheilkd.
2018;78:382–399.29720744
6
Leduc
D
,
Senikas
V
,
Lalonde
AB
. No 235‐active management of the third stage of labour: prevention and treatment
of postpartum hemorrhage. J Obstet Gynaecol Can. 2018;40:e841–e855.30527079
7
Organization
PAH
. Guidelines for the prevention, diagnosis and treatment of obstetric hemorrhage [in
Portuguese]. PAHO; 2018.
8
Fawcus
S
. Alerts for managing postpartum haemorrhage. S Afr Med J. 2018;108:1013–1017.
9
Sri Lanka College of Obstetrician and Gynecologists
. SLCOG Guideline on Management of Primary PostPartum Haemorrhage. Accessed August
11, 2021. https://www.slcog.lk/wp‐content/uploads/2021/02/SLCOG‐Guideline‐on‐Management‐of‐Primary‐Post‐Partum‐Haemorrhage‐03.‐2020.pdf
10
Fuchther
C
,
Ortiz
EI
,
Escobar
MF
,
Lizaola
H
. Hemorragia Postparto: en donde estamos y hacia donde vamos. Federación Latinoamericna
de Sociedades de Ginecologia y Obstetricia. Accessed August 11, 2021. https://www.flasog.org/static/libros/Hemorragia‐Postparto‐17OCTUBRE.pdf
11
Lalonde
A
; International Federation of Gynecology and Obstetrics
. Prevention and treatment of postpartum hemorrhage in low‐resource settings. Int
J Gynaecol Obstet. 2012;117(2):108–118.22502595
12
World Health Organization
. WHO recommendations: Uterotonics for the prevention of postpartum haemorrhage. Accessed
August 25, 2021. https://apps.who.int/iris/bitstream/handle/10665/277276/9789241550420‐eng.pdf?ua=1
13
Althabe
F
,
Therrien
MNS
,
Pingray
V
, et al. Postpartum hemorrhage care bundles to improve adherence to guidelines: A
WHO technical consultation. Int J Gynecol Obstet. 2020;148:290–299.
6.2
Guidelines that address the treatment of postpartum hemorrhage
PPH guidelines frequently recommend a multidisciplinary approach for reaching effective
early control of bleeding. Treatment should be directed to the specific cause of PPH
(uterine atony, genital trauma, retained placenta, and/or coagulopathy) and therapeutic
steps should move from the less invasive method to the more complex and radical approach.
A set of initial measures also seems to be consensual in most guidelines and consist
of maintenance of two large IV lines, supplementation of oxygen, strict monitoring
of women, crystalloids infusion, and measures to avoid hypothermia and evaluate the
PPH cause.
1
,
2
,
3
,
4
,
5
,
6
,
7
,
8
,
9
If atony is the etiology, most guidelines suggest performing temporary mechanical
measures, such as uterine massage or uterine bimanual compression, with concurrent
pharmacological treatment.
1
,
2
,
3
,
4
,
5
,
6
,
7
,
8
,
9
,
10
Uterotonics are considered the first‐line treatment for uterine atony. Intravenous
oxytocin is usually the preferred drug and route of administration, but its dosage
varies widely. When oxytocin fails to control PPH, guidelines recommend the use of
an additional drug, such as ergot alkaloids, injectable prostaglandins, or misoprostol.
1
,
2
,
3
,
4
,
6
,
7
,
8
,
10
SOGC mentions carbetocin as a uterotonic available for treatment,
5
and the German/Austrian/Swiss guidelines highlight that the use of carbetocin to treat
PPH is currently not sufficiently investigated
4
(Table 6).
TABLE 6
Summary of pharmacological treatment from high‐quality guidelines around the world
Guideline/year of publication
Pharmacological treatment
1st line uterotonic
Oxytocin
Ergot alkaloids
Misoprostol
Injectable prostaglandin
TXA
Carbetocin
FIGO 2012
Oxytocin
10 IU IM
or
20–40 IU in 1 L of normal saline at 60 drops per minute
Continue oxytocin infusion (20 IU in 1 L of IV fluid at 40 drops per minute) until
hemorrhage stops
Ergometrine or methylergometrine (used if oxytocin is not available or if bleeding
continues despite having used oxytocin): 0.2 mg IM or can be given slowly IV, repeated
every 2–4 h (maximum of 5 doses)
If oxytocin is not available or administration is not feasible):
Single dose of 800 μg sublingually (4×200 μg tablets)
Carboprost (should be offered as the third line of treatment): 0.25 mg IM Q15 min
(maximum 2 mg)
Not mentioned
Carbetocin recommended as a second‐line treatment: 100 μg IM or IV over 1 min
WHO 2012
Oxytocin
Does not specify
Ergometrine or oxytocin‐ergometrine if IV oxytocin fails or if it is not available.
Dosages not specified
800 μg sublingual if IV oxytocin fails or if it is not available
Does not specify
Use in all cases of PPH, regardless of the cause. Used as soon as possible. Dose:
1 g IV, over 10 min, within 3 h of birth, with a second dose of 1 g IV if bleeding
continues after 30 min or restart within 24 h of completing the first dose
FOGSI 2015
Oxytocin
10–40 IU in 1 L of normal saline
Methylergonovine 0.2 mg IM
800–1000 μg rectally;
200 μg orally plus 400 μg sublingually;
or
200 μg orally plus 400 μg rectally
250 μg IM every 15–90 min, as needed, up to a total dose of 2 mg
Not mentioned
Not mentioned
RCOG 2016
Oxytocin (preferred initially)
Oxytocin 5 IU, by slow IV injection (may have repeat dose); oxytocin infusion (40 IU
in 500 ml isotonic crystalloids at 125 ml/h) unless fluid restriction is necessary
Ergometrine 0.5 mg, slow IV or IM (contraindicated in women with hypertension)
800 μg sublingual
Carboprost 0.25 mg IM, repeated at intervals of not less than 15 min to a maximum
of 8 doses (use with caution in women with asthma)
Consider TXA 1 g IV
ACOG 2017
Healthcare provider's discretion
10–40 IU per 500–1000 ml as continuous infusion (IV) or 10 IU IM
Methylergonovine 0.2 mg IM, every 2–4 h.
Contraindicated in hypertension
600–100 μg, oral, sublingual, or rectal
Carboprost 0.25 mg IM, every 15–90 min, 8 doses maximum (can be used as intramyometrial).
Contraindicated in asthma
Should be considered when initial medical therapy fails. Earlier use is likely to
be superior to delayed treatment
CNGOF/SFA R 2016
Oxytocin
5–10 IU slow IV or IM followed by 5–10 IU/h, IV, for 2 h. Cumulative dose must not
exceed 40 IU (IM route is only an option for vaginal birth)
Not mentioned
It is not recommended as a second‐line treatment
Sulprostone within 30 min, if oxytocin fails
1 g, renewable once if ineffective the first time, limited to cases of sulprostone‐resistant
PPH
RANZCOG 2017
Does not clearly specify
5 IU by slow IV injection and 40 IU in an IV infusion over 4 h
Ergometrine 0.25 mg by slow IV or IM, repeated if necessary, every 5 min up to a maximum
of 1 mg; in the absence of contraindications
Up to 1000 μg rectally
Carboprost 0.25 mg IM, repeat as required at intervals of not less than 15 min up
to 8 doses (maximum 2 mg); or intramyometrial injection of 0.5 mg, under the responsibility
of the administering clinician Contraindicated if significant history of asthma
Dose: 1 g IV, with a clinical diagnosis of PPH. The dose is repeated after 30 min
if bleeding was persistent
SOGC 2018
Does not clearly specify
10 IU IM (consider ability of the medication to reach a uterus with poor tissue perfusion);
5 IU IV push; 20–40 IU in 250 ml of normal saline, infused IV at 500–1000 ml/h
Ergometrine 0.25 mg IM or IV, can be repeated every 2 h
400–800 μg; onset of effects is faster with oral or sublingual than rectally
800–1000 μg; effects are longer lasting with rectal than with oral
Carboprost 0.25 mg IM or intramyometrially; can be repeated every 15 min, to a maximum
of 2 mg (8 doses)
Asthma is a relative contraindication
Carbetocin: 100 µg IM or IV over 1 min
Not mentioned
Carbetocin recommended
German/Austrian/ Swiss 2018
Oxytocin
3––5 IU in 10 ml of NaCl 0.9% slow IV bolus. If necessary, it is followed by 10–40 IU
oxytocin in 500‐1000mL saline as a continuous infusion
Maximum of 6 IU undiluted oxytocin can be administered IV, slowly. Oxytocin IM only
if necessary
Not recommended routinely. If used, caution with adverse effects.
Methylergometrine should not be used as IV bolus. Does not mention dosages
If first‐line uterotonics are not effective: 800–1000 μg rectally or 600 μg orally
After administration of oxytocin may be considered
If first‐line uterotonics are ineffective. Option: sulprostone 500 μg in 500 ml IV
(pump). Initial dose: 100–500 ml/h.
Maintenance: 100 ml/h. Maximum 1000 μg/10 h or 1500 μg daily. Intramyometrial application
is contraindicated
Early use if required.
1–2 g (15–30 mg/kg), to be repeated as needed
Carbetocin not recommended
FLASOG 2018
Oxytocin
40 IU in 500 ml crystalloids at 60 ml per hour. Dose from 80–160 thousand units per
minute
Methylergonovine 0.2 mg IM, repeat if necessary, after 20 min and then every 4 h up
to a maximum of 5 doses
800 ug sublingual or rectal single dose
Not mentioned
1 g IV, the same dose can be repeated after 30 min if bleeding persists
Not mentioned
Abbreviations: TXA, tranexamic acid; FIGO, International Federation of Gynecology
and Obstetrics; IU, international unit; IM, intramuscular; IV, intravenous; WHO, World
Health Organization; FOGSI, Federation of Obstetric and Gynaecological Societies of
India; RCOG, Royal College of Obstetricians and Gynaecologists; ACOG, American College
of Obstetricians and Gynecologists; CNGOF/SFAR, College of Gynaecologists and Obstetricians/French
Society of Anesthesiology and Intensive Care; RANZCOG, Royal Australian and New Zealand
College of Obstetricians and Gynaecologists; SOGC, Society of Obstetricians and Gynaecologists
of Canada; DGGG/OEGGG/SSGO, German Society of Gynecology and Obstetrics/Austrian Society
of Obstetrics and Gynecology/Swiss Society of Gynaecology and Obstetrics, FLASOG,
Federación Latinoamericana de Sociedades de Obstetricia y Ginecología.
John Wiley & Sons, Ltd
Since publication of the World Maternal Antifibrolytic (WOMAN) trial,
11
tranexamic acid (TXA), an antifibrinolytic drug, has been incorporated into PPH guidelines
around the world.
4
,
6
,
7
,
8
,
9
,
10
,
12
,
13
WHO has updated this topic and recommends the use of TXA, as soon as possible, within
the first 3 h from birth, at a dose of 1 g intravenously, regardless of the route
of birth.
12
,
13
However, some guidelines do not cite it
5
or do not add it in a definitive manner because their last update occurred before
the WOMAN trial results.
1
,
2
Another drug that has been discussed in many guidelines is recombinant activated factor
VII for massive PPH; however, there is no consensus about its use.
1
,
2
,
3
,
4
,
5
,
6
When pharmacological treatment fails in controlling hemorrhage, guidelines usually
recommend some mechanical, radiological, and more conservative surgical approaches
before performing hysterectomy. The available guidelines are summarized in Table 6.
The most cited ones are uterine balloon tamponade (UBT), uterine compressive sutures
(UCS), pelvic vascular ligation (PVL), and embolization.
1
,
2
,
3
,
4
,
5
,
6
,
7
,
10
Uterine packing with gauze is also mentioned in some guidelines, but its use is controversial.
3
,
5
ACOG mentions the use of a gauze soaked with thrombin.
6
German/Austrian/Swiss guidelines cite the use of intrauterine packing with a gauze
coated with a hemostatic agent.
4
Due to the lack of evidence, guidelines do not necessarily recommend these conservative
approaches in a well‐defined, step‐wise progression, and their utilization depends
mainly on the availability of resources, professional familiarity with technique,
and clinical circumstances.
10
UBT is typically indicated as the treatment of choice when uterine atony is refractory
to uterotonics after vaginal delivery as it is less invasive than the other procedures.
1
,
2
,
3
,
6
,
7
,
8
,
9
This should be considered after ruling out retained products of conception, ruptured
uterus, or vaginal or cervical laceration as a contributing factor. If UBT fails to
control bleeding in these cases, invasive treatments by arterial embolization or,
most commonly, by surgical approaches are recommended (Table 7). UCS and/or PVL are
recommended to avoid hysterectomy when laparotomy is performed. The most mentioned
UCS techniques in guidelines are B‐Lynch, Hayman, and/or Cho sutures, while the most
cited PVL techniques are bilateral uterine and/or utero‐ovarian vessel ligations and,
less frequently, hypogastric ligature.
1
,
2
,
3
,
4
,
5
,
6
,
7
,
8
,
9
,
10
PVL and UCS can also be used together.
TABLE 7
Summary of postpartum hemorrhage mechanical, surgical, and radiological treatment
from high‐quality guidelines around the world
Guideline/year of publication
Mechanical, radiological, and surgical treatments
Tamponade technique
Compressive uterine sutures
Vessel ligation
Embolization
Hysterectomy
NASG
Other techniques
FIGO 2012
Bimanual compression of the uterus (external or internal). IBT recommended
B‐Lynch or Cho sutures should be tried first if bleeding does not stop despite treatment
with uterotonics or other conservative interventions
Uterine, utero‐ovarian, and hypogastric vessel ligation may be tried after compression
suture
Recommended
In case life‐threatening bleeding continues even after ligation
Recommended as a temporizing measure
Aortic compression
WHO 2012
Bimanual uterine compression: temporizing measure for atony at vaginal delivery.
IBT: if uterotonics fail or are not available; Uterine packing is not recommended
Compression sutures may be attempted as a first conservative surgical approach for
atony
Uterine, utero‐ovarian, and hypogastric vessel ligation may be tried after compression
suture
Recommended as a treatment for PPH due to uterine atony
When life‐threatening bleeding continues even after ligation, subtotal or total
Recommended as a temporizing measure
Uterine massage. External aortic compression as a temporizing measure
RCOG 2016
IBT: recommended as first‐line “surgical” intervention
B‐Lynch, Hayman
Stepwise uterine devascularization; Bilateral internal iliac ligation
Recommended, even after hysterectomy
Sooner rather than later (to discuss with a second experienced clinician if feasible)
Technique: subtotal
is preferred
Not mentioned
Compression of the aorta
Rub up the uterine fundus
FOGSI 2015
Bimanual compression–hand in vagina elevating uterus stretches uterine artery
B‐Lynch, Hayman, Cho suture
Stepwise devascularization: unilateral or bilateral; low uterine vessel ligation or
bilateral ovarian vessel ligation
Recommended when the routine medical and conservative methods of bleeding control
have been tried and not found effective
Last option, it reflects the failure of all other methods at stopping PPH
Mentioned:
Research was ongoing to evaluate the potential benefits and harms of this intervention
Compression of aorta against vertebrae useful emergency measure for 10 min
ACOG 2017
Bimanual uterine compression.
IBT: when uterotonics and bimanual uterine massage fail.
If balloon system is not available, pack with gauze
Secondary treatment for atony unresponsive to medical management.
Cited: B‐Lynch, Cho, and Hayman; can be associated with vessel ligations
When less invasive approaches fail; bilateral uterine artery (most common), utero‐ovarian
vessels, and/or internal iliac artery (less frequently
used)
Recommended in stable patient, with persistent slow bleeding and when less invasive
therapy has failed
When conservative therapies have failed as a definitive treatment
Not mentioned
Uterine massage
CNGOF/SFAR 2016
IBT: can be performed if sulprostone fails and before contemplating either surgery
or interventional radiology
In cases of PPH resistant to pharmacological treatment; can be associated with vessel
ligations; no technique for conservative surgery is favored over another
Ligation (bilateral ligation of the uterine arteries (BLUA) or bilateral ligation
of the internal iliac arteries (BLIIA). No technique for conservative surgery is favored
over another
Recommended
Massive PPH; if previous surgical procedure fails; total or subtotal
Not mentioned
Uterine massage
RANZCOG 2017
Bimanual compression; IBT: recommended
B‐Lynch
Bilateral ligation of uterine arteries; bilateral ligation of internal iliac arteries
by an experience operator
Recommended; it needs equipment and expertise; should not preclude other approaches
Sooner rather than later
Not mentioned
Uterine massage
Procedures should not necessarily be a stepwise progression and both order and utilization
will depend on the services/clinical experience and the individual clinical circumstances
SOGC 2018
Bimanual uterine compression: until further measures are taken, or assistance arrives.
IBT: when medical therapy fails for uterine atony; consider uterine packing
B‐Lynch, vertical compression, and Cho
Uterine and hypogastric artery ligation if bleeding continues (after compression sutures
in atony)
Option when there is active PPH, in a stable woman, and before surgical intervention
(it requires expertise and equipment)
Failure of previous interventions; subtotal or total
Not mentioned
Uterine massage; external aortic compression
German/Austrian/Swiss 2018
Bimanual uterine compression
UBT: does not preclude other necessary therapeutic options. Fill with liquid at body
temperature, not air)
Uterine packing with chitosan‐covered gauze (special gauze with hemostatic agent)
Strongly recommended, particularly to treat atony. Choice of appropriate suture depends
on indication (atony, bleeding from placental bed, diffuse bleeding)
In addition to simple ligature of uterine artery, stepwise uterine devascularization
can be performed. Ligature or internal iliac artery must only be carried out as a
last resort and only by experienced surgeon
Recommended; radiologist should be notified early (e.g. when compression suture is
unsuccessful)
Must not be delayed or left too late.
Total hysterectomy: should be considered for placental disorder. Supracervical: the
procedure of choice for atony
Not mentioned
Uterine massage
Bimanual compression of aorta
Pelvis‐abdominal packing: if bleeding persists after hysterectomy
FLASOG 2018
Bimanual uterine compression.
IBT: when uterotonics and bimanual uterine massage fail.
B‐Lynch, Hayman, Cho suture
Stepwise uterine devascularization; Bilateral internal iliac ligation. Recommended
according to the competencies of the medical staff
Recommended primarily for vaginal trauma when available
In case life‐threatening bleeding and when conservative therapies have failed as a
definitive treatment
Recommended as a temporizing measure and as part of the treatment
Compression of the aorta
Abbreviation: NASG, nonpneumatic antishock garment; IBT, uterine balloon tamponade;
FIGO, International Federation of Gynecology and Obstetrics; WHO, World Health Organization;
RCOG, Royal College of Obstetricians and Gynaecologists; FOGSI, Federation of Obstetric
and Gynaecological Societies of India; ACOG, American College of Obstetricians and
Gynecologists; CNGOF/SFAR: College of Gynaecologists and Obstetricians/French Society
of Anesthesiology and Intensive Care; RANZCOG, Royal Australian and New Zealand College
of Obstetricians and Gynaecologists; SOGC, Society of Obstetricians and Gynaecologists
of Canada; FLASOG, Federación Latinoamericana de Sociedades de Obstetricia y Ginecología.
John Wiley & Sons, Ltd
Embolization is also cited as a conservative therapeutic strategy; however, it is
most often indicated in places where specialized equipment and professionals are available
in a timely manner.
1
,
2
,
3
,
4
,
5
,
7
,
10
Therefore, these conditions may limit its use in acute bleedings.
If bleeding is severe, especially in low‐resource settings, some guidelines recommend
the use of temporizing measures such as aortic compression and, more recently, the
nonpneumatic antishock garment (NASG), to reduce blood loss until appropriate care
is available or while awaiting transfer to a higher‐level facility.
3
,
7
,
14
,
15
NASG has been recommended by WHO and FIGO for postpartum women with severe hemorrhage
showing signs of shock or hemodynamic instability at all levels of care, especially
at the primary healthcare level or if transport to a higher facility is necessary.
3
,
14
,
15
Regarding hysterectomy, it is usually recommended when other procedures have failed
to control massive bleeding or when they were not indicated. Guidelines highlight
that hysterectomy should be performed “sooner rather than later,” before the patient
develops coagulopathy.
1
,
2
,
3
,
4
,
5
,
6
,
7
,
9
,
10
Recently, damage control surgery (intra‐abdominal or pelvic packing) has been mentioned
in some PPH guidelines as an approach for critically ill patients with persistent
bleeding after hysterectomy.
4
,
7
Finally, many guidelines also address statements for the management of genital tract
trauma (especially uterine inversion and uterine rupture), coagulopathy disorders,
and retained placenta in obstetric patients. Because of the high maternal morbidity
and mortality related to the placenta accreta spectrum and its relation to the high
rates of cesarean deliveries in many countries around the world, FIGO and other medical
societies have specific guidelines for the placenta accreta spectrum.,
16
,
17
,
18
,
19
BOX 4
FIGO recommends the preparedness of obstetric care teams for the management of PPH
according to the updated guidelines established locally, regionally, or globally.
These guidelines should include medical and nonmedical treatment options according
to the degree of development of each country or region.
Local, regional, and national medical and nonmedical options for prevention and treatment
of PPH need to consider the resources available locally.
National societies are encouraged to lobby to establish a PPH bundle approach and
ensure availability of medical supplies and surgical equipment.
REFERENCES
1
Prevention and management of postpartum haemorrhage: green‐top guideline no. 52. BJOG.
2017;124:e106–e149.27981719
2
Sentilhes
L
,
Vayssière
C
,
Deneux‐Tharaux
C
, et al Postpartum hemorrhage: guidelines for clinical practice from the French College
of Gynaecologists and Obstetricians (CNGOF): in collaboration with the French Society
of Anesthesiology and Intensive Care (SFAR). Eur J Obstet Gynecol Reprod Biol. 2016;198:12–21.26773243
3
World Health Organization
. WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage.
Accessed August 18, 2021. https://www.who.int/reproductivehealth/publications/maternal_perinatal_health/9789241548502/en/
4
Schlembach
D
,
Helmer
H
,
Henrich
W
, et al. Peripartum haemorrhage, diagnosis and therapy. Guideline of the DGGG, OEGGG
and SGGG (S2k Level, AWMF Registry No. 015/063, March 2016). Geburtshilfe Frauenheilkd.
2018;78:382–399.29720744
5
Leduc
D
,
Senikas
V
,
Lalonde
AB
. No. 235‐active management of the third stage of labour: prevention and treatment
of postpartum hemorrhage. J Obstet Gynaecol Can. 2018;40:e841–e855.30527079
6
Committee on Practice Bulletins‐Obstetrics
. Practice bulletin no. 183: postpartum hemorrhage. Obstet Gynecol. 2017;130:e168–e186.28937571
7
Organization
PAH
. Guidelines for the prevention, diagnosis and treatment of obstetric hemorrhage [in
Portuguese]. PAHO; 2018.
8
Fawcus
S
. Alerts for managing postpartum haemorrhage. S Afr Med J. 2018;108:1013–1017.
9
Sri Lanka College of Obstetrician and Gynecologists
. SLCOG Guideline on Management of Primary PostPartum Haemorrhage. Accessed August
25, 2021. https://www.slcog.lk/wp‐content/uploads/2021/02/SLCOG‐Guideline‐on‐Management‐of‐Primary‐Post‐Partum‐Haemorrhage‐03.‐2020.pdf
10
Royal Australian and New Zealand College of Obstetricians and Gynaecologists
. RANZCOG statement. Management of postpartum hemorrhage. Accessed August 25, 2021.
https://ranzcog.edu.au/RANZCOG_SITE/media/RANZCOG‐MEDIA/Women%27s%20Health/Statement%20and%20guidelines/Clinical‐Obstetrics/Management‐of‐Postpartum‐Haemorrhage‐(C‐Obs‐43)‐Review‐July‐2017.pdf?ext=.pdf
11
WOMAN Trial Collaborators
. Effect of early tranexamic acid administration on mortality, hysterectomy, and other
morbidities in women with post‐partum haemorrhage (WOMAN): an international, randomised,
double‐blind, placebo‐controlled trial. Lancet. 2017;389:2105–2116.28456509
12
World Health Organization
. WHO Recommendation on Tranexamic Acid for the Treatment of Postpartum Haemorrhage.
Accessed August 21: 2021. https://www.who.int/reproductivehealth/publications/tranexamic‐acid‐pph‐treatment/en/
13
Vogel
JP
,
Oladapo
OT
,
Dowswell
T
,
Gülmezoglu
AM
. Updated WHO recommendation on intravenous tranexamic acid for the treatment of post‐partum
haemorrhage. Lancet Glob Health. 2018;6:e18–e19.29100880
14
Althabe
F
,
Therrien
MNS
,
Pingray
V
, et al. Postpartum hemorrhage care bundles to improve adherence to guidelines: a
WHO technical consultation. Int J Gynecol Obstet. 2020;148:290–299.
15
FIGO Safe Motherhood and Newborn Health Committee, International Federation of Gynecology
and Obstetrics
. Practice Guideline. Non‐pneumatic anti‐shock garment to stabilize women with hypovolemic
shock secondary to obstetric hemorrhage. Int J Gynecol Obstet. 2015;128:194–195.
16
Jauniaux
E
,
Ayres‐de‐Campos
D
; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel
. FIGO consensus guidelines on placenta accreta spectrum disorders: Introduction.
Int J Gynecol Obstet. 2018;140:261–264.
17
Jauniaux
E
,
Alfirevic
Z
,
Bhide
AG
, et al. Placenta praevia and placenta accreta: diagnosis and management. BJOG. 2019;126(1):e1–e48.30260097
18
American College of Obstetricians and Gynecologists; Society for Maternal‐Fetal Medicine
. Obstetric care consensus no. 7: placenta accreta spectrum. Obstet Gynecol. 2018;132:e259–e275.30461695
19
Fuchtner
C
,
Ortiz
EI
,
Escobar
MF
,
Lizaola
H
. Hemorragia Postparto: en donde estamos y hacia donde vamos. Federación Latinoamericana
de Sociedades de Ginecologia y Obstetricia. Accessed August 11, 2021. https://www.flasog.org/static/libros/Hemorragia‐Postparto‐17OCTUBRE.pdf
7
MEDICAL PREVENTION AND TREATMENT
7.1
Carbetocin versus oxytocin use in PPH: recent evidence
Oxytocin has been traditionally used as the first‐line uterotonic for the prevention
of PPH. Since 1992, carbetocin has been extensively tested in the management of PPH.
1
,
2
Beyond its uterotonic effects, carbetocin may also promote blood coagulation.
3
7.1.1
Clinical evidence for PPH prevention: oxytocin versus carbetocin (vaginal delivery)
The Heat‐Stable Carbetocin versus Oxytocin to Prevent Hemorrhage after Vaginal Birth
(CHAMPION) study provided new evidence comparing oxytocin and carbetocin.
4
It studied 29 645 women with cervical dilation <6 cm having a singleton pregnancy
and planned for vaginal delivery. Patients were randomized to receive intramuscular
injection of 100 µg heat‐stable carbetocin (Paban) or 10 IU oxytocin in 10 different
countries. The data showed that for PPH prevention, heat‐stable carbetocin was not
inferior to oxytocin administration for blood loss of at least 500 ml (RR 1.01; 95%
CI, 0.95–1.06) or the use of additional uterotonic agents. Noninferiority was not
shown for the outcome of blood loss of at least 1000 ml (RR 1.04; 95% CI, 0.87–1.25).
In this study, when the two drugs were compared, the following results were obtained:
in women with >500 ml blood loss, additional uterotonic agents were required in almost
15% of cases in both arms. When blood loss exceeded 1000 ml, the requirement for additional
uterotonics was only 1.5% in both arms.
3
Therefore, access to drugs is key since oxytocin has problems with drug purity in
low‐resource settings. The safety profile appeared to be similar for both drugs.
More recently, a network meta‐analysis including 140 randomized trials with data from
88 947 women was developed to identify the most effective uterotonic drug(s) to prevent
PPH and generate a ranking according to their effectiveness and adverse effect profile.
5
The data showed that compared with oxytocin, the combination of ergometrine plus oxytocin
had a risk ratio of 0.69 (95% CI, 0.57–0.83), and was more effective; however, with
only moderate quality evidence and with higher risk of adverse effects such as vomiting
and hypertension. For carbetocin, the risk ratio was 0.72 (95% CI, 0.52–1.00), and
although it was significant, there was very low‐quality evidence. Finally, for misoprostol
plus oxytocin the risk ratio was 0.73 (95% CI, 0.60–0.90), with moderate quality evidence
and higher risk of fever.
5
In a low‐risk setting there may be advantages to using well‐tested and readily available
drugs. When the carbetocin effect was compared with the use of rectal misoprostol
for preventing PPH in low‐risk patient populations in a randomized controlled trial
among 150 pregnant women, the data showed the superiority of carbetocin for efficacy.
6
This was evidenced in all indices tested; beyond blood loss, patients had a shorter
third stage of labor and reduced need for additional uterotonic drugs. Additionally,
adverse effects such as diarrhea, shivering, and fever were more pronounced with misoprostol
administration.
6
In a randomized controlled trial of patients with severe pre‐eclampsia, carbetocin
was shown to be a good alternative to oxytocin, requiring a lower volume per dose.
7
7.1.2
Clinical evidence for PPH prevention: oxytocin versus carbetocin (cesarean delivery)
Cesarean delivery is a surgical procedure requiring high skill, operating time, anesthesia,
intravenous fluids, and different drugs. The addition of carbetocin, therefore, is
expected to be of benefit and the need for a single drug administration reduces the
need for an intensive management team, which is generally required following a cesarean
delivery. A Cochrane review including 11 studies showed that despite a statistically
significant reduction in the need for further uterotonics in the carbetocin group
compared with oxytocin in women undergoing a cesarean delivery, no statistically significant
differences in terms of the risk of PPH were noted.
8
In 2018 a meta‐analysis to analyze the effectiveness of carbetocin compared with oxytocin
for the prevention of PPH in cesarean deliveries (seven studies involving 2012 patients)
demonstrated a significant reduction in the rates of PPH (RR 0.79; 95% CI, 0.66–0.94,
P = 0.009), use of additional uterotonics (RR 0.57; 95% CI, 0.49–0.65, P < 0.001),
and transfusion (RR 0.31; 95% CI, 0.15–0.64, P = 0.002) when carbetocin was used instead
of oxytocin. However, despite the potential benefits, the disparity between the cost
of carbetocin and oxytocin suggests that a locoregional cost‐effectiveness analysis
should be performed before making the decision to adopt carbetocin for routine prophylaxis.
9
In 2020, sequential trial analysis of five randomized controlled trials of studies
with data on women (a total of 1214) undergoing nonelective cesarean deliveries, where
carbetocin was compared with oxytocin, was performed.
10
The need for additional uterotonics was reduced with carbetocin compared with oxytocin
(OR 0.30; 95% CI, 0.11–0.86; I2, 90.60%). Trial sequential analysis (TSA) confirmed
that the information size needed to show a significant reduction in the need for additional
uterotonics had been exceeded. No significant differences were shown with respect
to any of the secondary outcomes, but there was significant heterogeneity between
the studies. The authors concluded that further trials utilizing consistent core outcomes
are needed to determine an effect on PPH.
10
On the other hand, a single center study was carried out to evaluate the cost‐effectiveness
of carbetocin compared with oxytocin when used for prophylaxis against PPH. With approximately
3000 cesarean deliveries per year, the study showed that the use of carbetocin could
prevent 108 episodes of PPH, 104 episodes of transfusion, and 455 patients would require
fewer uterotonics. Their cost‐saving per PPH case was USD$ 278.70.
11
Another study where 1500 cesarean deliveries (both elective and emergency) were analyzed
over 12 months, carbetocin use, as opposed to oxytocin use, reduced 30 (88 vs 58)
PPH events (>500 ml blood loss) and saved £27 518. Carbetocin had a 91.5% better outcome
and was 69.4% cheaper.
12
When compared with the need for additional uterotonics in the carbetocin group, none
required additional medication versus 71.5% in the oxytocin group (P < 0.01). In another
prospective cohort study, carbetocin used for 400 patients undergoing cesarean delivery
led to reduced PPH and the use of other oxytocic agents, saving £68.93 per patient.
13
In 2019, a systematic review of the cost‐effectiveness of uterotonic agents for the
prevention of PPH was published with 15 studies across all income categories that
compared misoprostol versus no uterotonic (five studies) or versus oxytocin (one study),
carbetocin versus oxytocin (eight studies), and one study comparing numerous uterotonics.
14
The evidence on the cost‐effectiveness of various uterotonic agents was not generalizable
to different contexts. In the absence of reliable evidence, the choice of uterotonic
will likely be highly influenced by uterotonic price and contextual factors. In the
context of cesarean delivery, carbetocin was more cost favorable than oxytocin. The
authors concluded the quality of the evidence provided by these studies has a lack
of sensitivity analyzes and incomplete description of the methods of outcome and costs
measurements in most studies. In addition, some studies from middle‐income countries
favoring carbetocin were funded by the manufacturer. They interpreted findings from
these studies and those of the conference abstracts with limited data cautiously,
owing to the potential risk of bias and imprecision. Therefore, it can be easily inferred
that the relative cost‐effectiveness of carbetocin is still inconclusive.
Beyond its primary efficacy, which is reduced blood loss, a drug's safety profile
must also be considered before wide‐scale utilization. The adverse effects of carbetocin
and oxytocin were examined in a small, randomized study.
15
The data showed that carbetocin had a lower rate of nausea. In contrast with other
clinical indices, including the need to stabilize systolic blood pressure and heart
rate, no other differences were noted.
15
Since anesthesiologists administer carbetocin for cesarean delivery, the requirement
for increased dose beyond the standard 100 ug in some instances was raised.
16
The longer half‐life of carbetocin prevents additional dosing in case of a persistent
bleed and does not permit additional oxytocin administration. The increase in carbetocin
dose from 100 µg to 140 µg injection increases cardiovascular complications.
17
Thus, in cases of pre‐eclampsia, close attention is warranted for preserving patient
safety before high dose carbetocin is administered. Also, in those cases, oxytocin
doses must be increased to control bleeding beyond the standard treatment, mainly
if the drug was used during labor, which may also increase complications rate. A case
report showed that carbetocin administration for a patient with asthma led to nearly
fatal bronchospasm and cardiac arrest requiring resuscitation, which was successful.
18
Therefore, this drug should be used with caution in patients with asthma or those
with advanced pulmonary pathology. This and other studies show inconsistency in adverse
events data and indicate that the utility of carbetocin should be further assessed
in additional pregnancy pathologies to establish the population in which the risk–benefit
profile is favorable.
BOX 5
FIGO reaffirms its recommendation regarding oxytocin as the first choice for prevention
of PPH in vaginal and cesarean deliveries.
In settings where oxytocin is unavailable (or its quality cannot be guaranteed), the
use of other uterotonics (carbetocin, ergometrine/methylergometrine, or misoprostol)
is recommended.
REFERENCES
1
Hunter
DJ
,
Schulz
P
,
Wassenaar
W
. Effect of carbetocin, a long‐acting oxytocin analog on the postpartum uterus. Clin
Pharmacol Ther. 1992;52:60–67.1623693
2
Arrowsmith
S
,
Wray
S
. Oxytocin: its mechanism of action and receptor signalling in the myometrium. J Neuroendocrinol.
2014;26:356–369.24888645
3
Gallos
ID
,
Coomarasamy
A
. Carbetocin: worth the extra expense?
Best Pract Res Clin Obstet Gynaecol. 2019;61:55–65.31164260
4
Widmer
M
,
Piaggio
G
,
Nguyen
TMH
, et al Heat‐stable carbetocin versus oxytocin to prevent hemorrhage after vaginal
birth. N Engl J Med. 2018;379:743–752.29949473
5
Gallos
ID
,
Williams
HM
,
Price
MJ
, et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta‐analysis.
Cochrane Database Syst Rev. 2018;(4):CD011689.
6
Maged
AM
,
Waly
M
,
Fahmy
RM
, et al Carbetocin versus rectal misoprostol for management of third stage of labor
among women with low risk of postpartum hemorrhage. Int J Gynecol Obstet. 2020;148:238–242.
7
Reyes
OA
,
Gonzalez
GM
. Carbetocin versus oxytocin for prevention of postpartum hemorrhage in patients with
severe preeclampsia: a double‐blind randomized controlled trial. J Obstet Gynaecol
Can. 2011;33:1099–1104.22082783
8
Su
LL
,
Chong
YS
,
Samuel
M
. Carbetocin for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2012;(2):CD005457.
9
Voon
HY
,
Suharjono
HN
,
Shafie
AA
,
Bujang
MA
. Carbetocin versus oxytocin for the prevention of postpartum hemorrhage: A meta‐analysis
of randomized controlled trials in cesarean deliveries. Taiwan J Obstet Gynecol. 2018;57:332–339.29880160
10
Onwochei
DN
,
Owolabi
A
,
Singh
PM
,
Monks
DT
. Carbetocin compared with oxytocin in non‐elective Cesarean delivery: a systematic
review, meta‐analysis, and trial sequential analysis of randomized‐controlled trials.
Can J Anaesth. 2020;67(11):1524–1534.32748189
11
Voon
HY
,
Shafie
AA
,
Bujang
MA
,
Suharjono
HN
. Cost effectiveness analysis of carbetocin during cesarean section in a high volume
maternity unit. J Obstet Gynaecol Res. 2018;44:109–116.29027315
12
Van der Nelson
HA
,
Draycott
T
,
Siassakos
D
,
Yau
CWH
,
Hatswell
AJ
. Carbetocin versus oxytocin for prevention of post‐partum haemorrhage at caesarean
section in the United Kingdom: an economic impact analysis. Eur J Obstet Gynecol Reprod
Biol. 2017;210:286–291.28088109
13
Luni
Y
,
Borakati
A
,
Matah
A
,
Skeats
K
,
Eedarapalli
P
. A prospective cohort study evaluating the cost‐effectiveness of carbetocin for prevention
of postpartum haemorrhage in caesarean sections. J Obstet Gynaecol. 2017;37:601–604.28317421
14
Lawrie
TA
,
Rogozińska
E
,
Sobiesuo
P
,
Vogel
JP
,
Ternent
L
,
Oladapo
OT
. A systematic review of the cost‐effectiveness of uterotonic agents for the prevention
of postpartum hemorrhage. Int J Gynaecol Obstet. 2019;146(1):56–64.
15
Mannaerts
D
,
Van der Veeken
L
,
Coppejans
H
,
Jacquemyn
Y
. Adverse effects of carbetocin versus oxytocin in the prevention of postpartum haemorrhage
after caesarean section: a randomized controlled trial. J Pregnancy. 2018;2018:1374150.29484209
16
Muggleton
E
. Oxytocin study raises concerns about carbetocin use. Anesth Analg. 2018;126:1423.
17
Nguyen‐Lu
N
,
Carvalho
JC
,
Farine
D
,
Seaward
G
,
Ye
XY
,
Balki
M
. Carbetocin at cesarean delivery for labour arrest: a sequential allocation trial
to determine the effective dose. Can J Anaesth. 2015;62(8):866–874.25860126
18
Pérez‐Nieto
OR
,
Castañón‐González
JA
,
Lima‐Lucero
IM
,
Delsol
LAG
. Near fatal bronchospasm and bradycardia after carbetocin administration. Med Intensiva.
2018;42:319–321.28554581
8
TRANEXAMIC ACID
Tranexamic acid (TXA) is a synthetic analogue of the amino acid lysine that inhibits
fibrinolysis by reducing the binding of plasminogen and tissue plasminogen activator
(tPA) to fibrin.
1
Labeled indications of this medication are cyclic heavy menstrual bleeding, and oral
procedures in patients with hemophilia. An antifibrinolytic drug is useful because
hyperfibrinolysis and fibrinogen depletion are common in the early stages of major
postpartum bleeding, and although existing medical and surgical interventions can
be used to treat postpartum bleeding, TXA offers an alternative way to support hemostasis.
8.1
Administration of TXA
Administration of TXA is recommended as soon as the diagnosis of PPH is made if the
diagnosis is made within 3 h of delivery. When more than 3 h has elapsed since delivery,
there is no clear evidence of benefit from TXA administration. TXA for PPH treatment
is given 1 g IV over 10 min within 3 h of vaginal or cesarean delivery. One gram (10 ml
of a 100 mg/ml solution) is infused over 10–20 min because infusion >1 ml/min can
cause hypotension. If bleeding continues after 30 min or stops and restarts within
24 h after the first dose, a second dose of 1 g may be given. The antifibrinolytic
effect lasts up to 7–8 h in the serum. The concentration in breast milk is approximately
one hundredth of the serum peak concentration, so it is unlikely to have antifibrinolytic
effects in the infant.
2
,
3
The WOMAN trial found that administration of TXA within 3 h of delivery to women with
established PPH decreases maternal mortality secondary to bleeding and reduces the
need for laparotomy to control hemorrhage.
2
TXA, as a management strategy, in addition to uterotonics reduced the risk of PPH
in randomized trials. Its use is effective in high‐risk clinical settings (e.g. delivery
of patients who refuse blood products, patients with a significant risk for PPH such
as placenta accreta or placenta previa or previous PPH). Usually, 1 g TXA intravenously
is recommended within 10 min after vaginal delivery in addition to oxytocin, cord
traction, and uterine massage.
4
,
5
A Cochrane review of antifibrinolytic agents used for the treatment for PPH identified
three eligible trials, two of which compared intravenous TXA with placebo or standard
care (the WOMAN trial and a French trial).
4
,
6
A meta‐analysis of 20 172 women from the WOMAN trial and the French trial (152 women
with PPH received high‐dose TXA, a loading dose of 4 g over 1 h followed by an infusion
of 1 g over 6 h) showed that TXA reduces the risk of death due to bleeding (RR 0.81;
95% CI, 0.65–1.00), with early treatment being more effective. WHO updated its recommendation
on the early use of TXA for the treatment of PPH (within 3 h of birth) with intravenous
TXA using the same dosing regimen as in the WOMAN trial: a fixed dose of 1 g in 10 ml
(100 mg/ml) intravenously at a rate of 1 ml/min. A second 1 g intravenous dose should
be administered if bleeding continues after 30 min or restarts within 24 h of the
first dose.
TXA should be given to all women with clinically estimated blood loss of more than
500 ml after vaginal birth or 1000 ml after cesarean delivery, or any blood loss that
is sufficient to compromise hemodynamic stability, regardless of the cause of hemorrhage.
TXA forms a reversible complex that displaces plasminogen from fibrin resulting in
inhibition of fibrinolysis and inhibition of the proteolytic activity of plasmin.
TXA is recommended for PPH management. It is given concomitantly with other drugs
and procedures for control of bleeding. An antifibrinolytic drug is useful because
hyperfibrinolysis and fibrinogen depletion are common in the early stages of major
postpartum bleeding. Delay in treatment, even if short, reduces the benefit of TXA
administration. The WOMAN trial found that TXA reduced death due to bleeding in women
with PPH by 20%–30% and was not associated with an increase in adverse effects. It
also reduced the incidence of laparotomy to control bleeding by 36% but did not reduce
hysterectomy rates. However, the decision to perform hysterectomy was sometimes made
at the same time as randomization, so some hysterectomies were performed before or
concurrently with administration of TXA.
2
,
3
8.2
TXA as a prophylactic measure
Although the WOMAN trial presents evidence for the use of TXA to treat established
PPH, there is limited evidence for its role in prevention of PPH. Reviews and meta‐analyses
of multiple trials have shown that prophylactic use of TXA may decrease both postpartum
bleeding and the need for blood transfusions.
7
,
8
However, larger adequately powered, multicenter randomized controlled trials are needed
before the prophylactic use of TXA can be recommended for the prevention of PPH. In
2021, a multicenter, double‐blind, randomized controlled trial was conducted with
4551 women undergoing cesarean delivery before or during labor at 34 or more gestational
weeks who received an intravenously administered prophylactic uterotonic agent and
either TXA (1 g) or placebo. Among women who underwent cesarean delivery and received
prophylactic uterotonic agents, TXA treatment resulted in a significantly lower incidence
of calculated estimated blood loss greater than 1000 ml or red‐cell transfusion by
day 2 compared with placebo, but it did not result in a lower incidence of hemorrhage‐related
secondary clinical outcomes.
9
Several systematic reviews related to the treatment of PPH exist. Mousa et al.
10
conducted a review that sought to include studies examining the effectiveness of all
types of treatments for PPH. However, their review primarily included studies involving
treatment with misoprostol, and little evidence regarding TXA. They concluded that
more research was needed regarding the effectiveness of TXA for treatment of PPH.
10
Additionally, the existing systematic reviews that examined TXA for prophylaxis against
PPH (where all laboring patients receive TXA) did not address the potential effects
of administering TXA only to mothers with PPH.
11
FIGO does not recommend the use of TXA prophylactically, given the limited evidence
in that regard.
8.3
Adverse reactions to TXA
Greater than 10%: headache (oral: 50%), abdominal pain (oral: 20%), back pain (oral:
21%), musculoskeletal pain (oral: 11%), nasal signs and symptoms (oral: 25%; including
sinus symptoms).
1%–10%: fatigue (oral: 5%), anemia (oral: 6%), arthralgia (oral: 7%), muscle cramps
(oral: ≤7%), muscle spasm (oral: ≤7%).
Less than 1%: allergic dermatitis, allergic skin reaction, anaphylactic shock, anaphylactoid
reaction, anaphylaxis, cerebral thrombosis, chromatopsia, conjunctivitis (ligneous),
deep vein thrombosis, diarrhea, dizziness, hypersensitivity reaction, hypotension
(with rapid intravenous injection), nausea, pulmonary embolism, renal cortical necrosis,
retinal artery occlusion, retinal vein occlusion, seizure, ureteral obstruction, visual
disturbance, vomiting.
8.4
Contraindications
Hypersensitivity to TXA or any component of the formulation.
8.5
Implementation of treatment with TXA
TXA should always be readily available in obstetric care facilities. It is cost‐effective,
heat stable, and widely available with a long shelf life. An economic evaluation that
used data from the WOMAN trial to assess the cost‐effectiveness of early TXA for usual
care of women with PPH in Nigeria and Pakistan concluded that it is likely to be highly
cost‐effective.
4
TXA should be used in addition to all usual treatments for the management of PPH including
medical (uterotonics), nonsurgical, and surgical interventions.
2
,
3
It has a wide therapeutic index, and a further intravenous injection could be given
when this becomes possible. Alternative routes of administration should be a research
priority, as recommended by WHO.
12
Owing to improvements in emergency obstetric care, including use of TXA as a first‐line
therapy, more women will survive PPH than ever before. Furthermore, the incidence
of PPH is increasing,
1
and consequently the number of women who will experience its physical and psychological
consequences will also increase. More research is needed on how to reduce the risk
factors for PPH
.
BOX 6
FIGO recommends administration of tranexamic acid as soon as the diagnosis of PPH
is made, as long as this is within 3 h postpartum.
One gram of tranexamic acid, intravenously over 10 min is to be given regardless of
the cause of PPH. If bleeding continues after 30 min or stops and restarts within
24 h after the first dose, a second dose of 1 g may be given.
REFERENCES
1
Ker
K
,
Edwards
P
,
Perel
P
,
Shakur
H
,
Roberts
I
. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative
meta‐analysis. BMJ. 2012;344:e3054.22611164
2
WOMAN Trial Collaborators
. Effect of early tranexamic acid administration on mortality, hysterectomy, and other
morbidities in women with post‐partum haemorrhage (WOMAN): an international, randomised,
double‐blind, placebo‐controlled trial. Lancet. 2017;389:2105–2116.28456509
3
Gayet‐Ageron
A
,
Prieto‐Merino
D
,
Ker
K
, et al. Effect of treatment delay on the effectiveness and safety of antifibrinolytics
in acute severe haemorrhage: a meta‐analysis of individual patient‐level data from
40 138 bleeding patients. Lancet. 2018;391:125–132.29126600
4
Shakur
H
,
Beaumont
D
,
Pavord
S
,
Gayet‐Ageron
A
,
Ker
K
,
Mousa
HA
. Antifibrinolytic drugs for treating primary postpartum haemorrhage. Cochrane Database
Syst Rev. 2018;(2):CD012964.29462500
5
Saccone
G
,
Della Corte
L
,
D’Alessandro
P
, et al Prophylactic use of tranexamic acid after vaginal delivery reduces the risk
of primary postpartum hemorrhage. J Matern Fetal Neonatal Med. 2020;33:3368–3376.30704334
6
Ducloy‐Bouthors
A‐S
,
Jude
B
,
Duhamel
A
, et al High‐dose tranexamic acid reduces blood loss in postpartum haemorrhage. Crit
Care. 2011;15:R117.21496253
7
Alam
A
,
Choi
S
. Prophylactic use of tranexamic acid for postpartum bleeding outcomes: a systematic
review and meta‐analysis of randomized controlled trials. Transfus Med Rev. 2015;29:231–241.26282735
8
Sentilhes
L
,
Lasocki
S
,
Ducloy‐Bouthors
AS
, et al Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Br J Anaesth. 2015;114:576–587.25571934
9
Sentilhes
L
,
Sénat
MV
,
Le Lous
M
, et al Tranexamic acid for the prevention of blood loss after cesarean delivery.
N Engl J Med. 2021;384:1623–1634.33913639
10
Mousa
HA
,
Blum
J
,
Abou El Senoun
G
,
Shakur
H
,
Alfirevic
Z
. Treatment for primary postpartum haemorrhage. Cochrane Database Syst Rev. 2014;(2):CD003249.24523225
11
Novikova
N
,
Hofmeyr
GJ
,
Cluver
C
. Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database Syst Rev.
2015;(6):CD007872.26079202
12
Kramer
MS
,
Berg
C
,
Abenhaim
H
, et al Incidence, risk factors, and temporal trends in severe postpartum hemorrhage.
Am J Obstet Gynecol. 2013;209(449):e1–7.
9
NONSURGICAL CONSERVATIVE MANAGEMENT
9.1
Nonpneumatic antishock garment (NASG)
The NASG is a low‐technology, affordable, first‐aid compression device for the management
and stabilization of women with hypovolemic shock due to PPH and management of refractory
PPH.
1
This device serves as a temporizing measure to recover hemodynamic stability to allow
definitive surgical interventions, blood transfusions, or transfer to more specialized
healthcare facilities.
2
,
3
,
4
The NASG is a lightweight, lower body compression device comprising six articulated
neoprene and hook‐and‐loop fastener segments that provide lower body circumferential
counterpressure to improve cardiac output and blood pressure.
5
The estimated circumferential pressure applied by the NASG is around 20–40 mm Hg.
Direct abdominal and pelvic compression reduces the total vascular space in the lower
body and decreases pelvic perfusion to pelvic compartment organs and smaller pelvic
blood vessels, promoting hemorrhage arrest.
6
Additionally, the pressure applied increases cardiac output and the central circulation,
allowing an increased distribution of blood flow to vital upper body organs (heart,
lung, brains) and contributing to a rapid recovery from shock.
1
,
7
Likewise, the direct compression of the descending aorta reduces bleeding from the
uterine arteries and the mesenteric bed's vasculature, perhaps decreasing up to 90%
of blood flow at the level of the superior mesenteric artery.
1
,
8
A further property of the NASG that makes it useful for maternal hemorrhage is the
easy access to the vagina and perineum, thereby facilitating genital medical and surgical
interventions. Additionally, it is extremely cost‐effective even for very low‐resource
settings, and is reusable as it can be disinfected and washed over 100 times without
losing its compressive effects.
3
It is also adjustable for many women of different girths and heights.
9.1.1
Safety
According to human studies, the NASG is a safe device, with no adverse effects such
as abdominal wall lesions or other types of potential injuries secondary to the circumferential
pressure applied, independent of the patient's body mass index or the strength used
to close each of the segments of the garment.
2
In multiple studies, there were no adverse events associated with NASG use: no increased
rates of dyspnea, cardiac, or renal dysfunctions. In fact, in all studies of NASG
involving extremely ill women with severe PPH, there were decreased rates of all severe
maternal morbidities.
4
Doppler studies of the distal aorta when the NASG is applied have shown a drop in
the flow rate (volume/time) up to 33%. Additionally, when the garment's abdominal
and pelvic segments are placed, the resistive index (inversely proportional to flow
rate) of the internal iliac arteries increases.
7
9.1.2
Effectiveness and advantages
Multiple studies have been carried out to assess the efficacy and effectiveness of
the NASG. Observational quasi‐experimental studies at referral centers in Egypt, Nigeria,
India, Zambia, and Zimbabwe showed a 48% drop in maternal mortality related to hypovolemic
shock (secondary to PPH).
2
Overall, the groups that received NASG treatment required fewer transfers to higher
complexity facilities as well as abdominal hysterectomies (for definitive therapeutic
approach) than women in the control groups, with a relative risk of 0.44 (95% CI,
0.23–0.86).
9
A randomized controlled trial implemented in Zambia and Zimbabwe demonstrated that
early placement of the NASG at primary healthcare centers was associated with a statistically
significant decline in shock recovery time (defined as shock index <0.9), with a median
time to recovery of 170 min for the NASG group versus 209 min for the control group,
with a hazard ratio of 1.2 (95% CI, 1.02–1.52, P = 0.03). Although the reduction in
mortality and severe maternal morbidities (54%) in this study was not statistically
significant (perhaps due to much smaller sample size than was necessary to show statistical
significance), it is still significant considering the seriousness of the outcomes.
10
In 2015, a systematic review of quasi‐experimental studies and the trial above compared
PPH standard care versus standard care plus NASG. It found that the use of the NASG
combined with standard PPH care reduces both maternal mortality (48%), with a relative
risk of 0.52 (95% CI, 0.36–0.77) and a 68% reduction in combined adverse outcomes,
mortality, and severe morbidities (RR 0.31; 95% CI, 0.17–0.59). Furthermore, safety
was demonstrated by the absence of differences in adverse events among groups.
2
Effectiveness outside of clinical trials has been reported in one large implementation
project in Tanzania that was conducted in 280 healthcare facilities in four rural
regions, with over 1700 women with PPH, 24.5% (n = 419) of whom had severe PPH and
hypovolemic shock.
11
Of these women, 70.8% received the NASG, which indicated high utilization and high
acceptability. There was also a temporal association of a 67% reduced risk of mortality
among women with severe PPH during the project (RR 0.33; 95% CI, 0.16–0.60).
Use of the NASG is recommended for the clinical stabilization and safe transfer to
high complexity centers in the clinical scenario of PPH. This device is currently
used in over 50 countries worldwide, and it has been recommended in many national
and international guidelines such as GLOWM, WHO, FIGO, and others.
12
,
13
,
14
,
15
This device should be present in every healthcare facility, as it has proven to be
effective and safe, granting significant reductions in PPH‐related mortality.
3
,
15
,
16
Besides the acceptability demonstrated in the Tanzania study, qualitative research
in a few settings has reported high acceptability from women and providers.
11
,
17
,
18
,
19
9.1.3
Indications
Women with PPH presenting with clinical signs or laboratory findings compatible with
shock or hemodynamic instability are suitable for treatment with the NASG. It is important
to note that the garment serves as a temporizing measure. Thus, once hemodynamic stability
is restored, patients should receive definitive medical and surgical treatment. Table 8
provides a reference for the indications for NASG application.
3
TABLE 8
Indications for NASG application
a
FIGO recommendations on use of the nonpneumatic anti‐shock garment for hypovolemic
shock secondary to obstetric hemorrhage
Population
Any pregnant or postpartum woman with severe hemorrhage showing signs of shock/hemodynamic
instability, at the primary healthcare level or if transport to higher facility is
necessary: EBL 500 ml, SBP <100 mm Hg, pulse >100 bpm; at high‐level facilities: EBL
>1000 ml, SBP <90 mm Hg, pulse >110 bpm (or per facility protocols)
Recommendation
Rapidly apply NASG starting at the ankles. NASG to remain in place until source of
bleeding found, and bleeding decreased to 25–50 ml/h
Scientific evidence
4 pre/post studies, 1 randomized controlled trial, 1 systematic review
Modifications
Depending on capacity of facility and staff, the NASG could either be applied as first‐line
first aid before any other intervention or could be used to reverse shock when other
methods to stop bleeding have failed, or while awaiting definitive therapy (embolization,
surgery, blood transfusions)
Grade
B (temporizing measure)
Abbreviations: EBL, estimated blood loss; SBP, systolic blood pressure; NASG, nonpneumatic
anti‐shock garment.
a
Source: FIGO Safe Motherhood and Newborn Health Committee [3]. Reproduced with permission
from FIGO.
John Wiley & Sons, Ltd
9.1.4
Instructions for use
The NASG is composed of six articulated segments. The first three segments are bilateral
and independent segments for the lower body parts: ankles, calves, and thighs. The
other three circumferential segments are placed over the pelvic and abdominal areas.
It must first be unfolded entirely and placed under the patient's body. To assure
proper application of the garment, placement of the superior edge of segment 6 (the
superior segment) over the lower rib should be confirmed. The device can be adjusted
to all sizes and heights. For instance, in shorter patients, segment 1 can be folded
into segment 2 to keep the first applied segment at the ankle and it can be performed
whenever someone who is competent to insert it is available.
For garment applications, each segment must be stretched and closed as tightly as
possible, starting at the ankles with segment 1 and continuing with the remaining
segments successively.
5
It is important to try to keep both knees uncovered by the leg segments to preserve
joint mobility. The leg segments of the NASG can be placed by one or two people, depending
on the availability of healthcare personnel. Appliers can use the pubic symphysis
as an anatomical reference point for placing segment 4. Appliers can use the umbilicus
as guidance for placing segments 5 and 6. Although all segments should be closed firmly
and tightly, the abdominal section must not be closed too tightly in order to maintain
adequate respiration. For that reason, it is advised that only one person should close
segments 5 and 6. If there is more than one person available, two people can coordinate
their actions, with one person presenting the opposite segment to the person who will
close both segments together. If the patient shows signs of respiratory distress,
abdominal segments (5 and 6) can be loosened, but not completely opened.
If the patient requires surgical intervention the leg sections should remain closed,
while the pelvic and abdominal segments can be temporarily opened, just before the
skin incision is made, and then closed once the procedure is concluded. In addition,
a drop in blood pressure should be expected when the abdominal and pelvic segments
are opened, and hence appropriate measures should be taken.
9.1.5
Monitoring and removal
Patients using the NASG should be closely followed with continuous monitoring of heart
rate and blood pressure and optimal fluid resuscitation.
5
This device can be used safely for up to 48 h as a temporizing measure until hemodynamic
stability or adequate hemorrhage control is achieved. Nevertheless, there are reports
of the NASG used for longer than 72 h. To safely remove the NASG, healthcare professionals
must verify the following criteria: blood loss <50 ml/h, heart rate <100 bpm, and
systolic blood pressure ≥100 mm Hg (rule of 100’s) for at least 2 h.
5
Once the following criteria are corroborated, it is safe to start removing the garment.
The intravenous line should remain in situ during the removal. Removal should follow
the same steps as application, starting with segment 1 at the ankles and moving slowly
up to segment 6. Every time a segment is opened, a 15‐min period is allowed to re‐evaluate
vital signs and check for active bleeding. If vital signs remain stable and there
are no signs of active bleeding, it is safe to open the next segment. However, if
systolic blood pressure drops ≥20 mm Hg or heart rate increases ≥20 bpm (rule of 20’s)
or active bleeding is identified, all of the segments must be rapidly closed again.
Once removed, the NASG should be placed in a biohazard container and sent to be laundered,
dried, and refolded. Videos and presentation slides of correct application, use, removal,
and cleaning can be obtained for free at: www.safemotherhood.ucsf.edu. These instructions
must be followed strictly, as incorrect removal of the garment could result in hemodynamic
instability and recurrence of shock, especially if the abdominal segment is the first
segment to be opened.
5
In the absence of hemodynamic instability signs, the whole garment can be removed
in 1 h and 15 min. Routine follow‐up laboratories, including hemoglobin and hematocrit
are encouraged. Values over 7.5 mg/dl of hemoglobin and a hematocrit >23% are recommended;
however, there is neither consensus nor evidence about these values, and further research
is needed.
9.1.6
Adverse effects
Currently, no adverse effects have been documented with correct implementation of
the NASG
4
; no increase in shock‐related organ dysfunction adverse effects have been noted.
9
9.1.7
Contraindications
Currently, there are no absolute medical contraindications for NASG use.
3
Cardiac and pulmonary comorbidities such as heart failure, severe mitral stenosis,
and pulmonary hypertension are considered relative contraindications in nonobstetric
patients. Although in severe hemorrhage, benefits are thought to outweigh any potential
harm.,
5
BOX 7
FIGO recommends that all healthcare facilities have the NASG as an effective nonsurgical
device that can be used as a temporary measure to recover hemodynamic stability for
the management and transfer of a patient to a high level of care.
REFERENCES
1
Escobar
MF
,
Füchtner
CE
,
Carvajal
JA
, et al Experience in the use of non‐pneumatic anti‐ shock garment (NASG) in the management
of postpartum haemorrhage with hypovolemic shock in the Fundación Valle Del Lili,
Cali, Colombia. Reprod Health. 2017;14:58.28499381
2
Pileggi‐Castro
C
,
Nogueira‐Pileggi
V
,
Tunçalp
Ö
,
Oladapo
OT
,
Vogel
JP
,
Souza
JP
. Non‐pneumatic anti‐shock garment for improving maternal survival following severe
postpartum haemorrhage: a systematic review. Reprod Health. 2015;12:28.25889868
3
FIGO Safe Motherhood and Newborn Health Committee, International Federation of Gynecology
and Obstetrics
. Non‐pneumatic anti‐shock garment to stabilize women with hypovolemic shock secondary
to obstetric hemorrhage. Int J Gynecol Obstet. 2015;128:194–195.
4
Althabe
F
,
Therrien
MNS
,
Pingray
V
, et al. Postpartum hemorrhage care bundles to improve adherence to guidelines: a
WHO technical consultation. Int J Gynecol Obstet. 2020;148:290–299.
5
Miller
S
,
Martin
HB
,
Morris
JL
. Anti‐shock garment in postpartum haemorrhage. Best Pract Res Clin Obstet Gynaecol.
2008;22:1057–1074.18805742
6
Kerr
NL
,
Hauswald
M
,
Tamrakar
SR
,
Wachter
DA
,
Baty
GM
. An inexpensive device to treat postpartum hemorrhage: a preliminary proof of concept
study of health provider opinion and training in Nepal. BMC Pregnancy Childbirth.
2014;14:81.24564622
7
Lester
F
,
Stenson
A
,
Meyer
C
,
Morris
J
,
Vargas
J
,
Miller
S
. Impact of the Non‐pneumatic Antishock Garment on pelvic blood flow in healthy postpartum
women. Am J Obstet Gynecol. 2011;204(409):e1–5.
8
Hauswald
M
,
Greene
ER
. Regional blood flow after pneumatic anti‐shock garment inflation. Prehosp Emerg
Care. 2003;7:225–228.12710783
9
Mourad‐Youssif
M
,
Ojengbede
OA
,
Meyer
CD
, et al Can the Non‐pneumatic Anti‐Shock Garment (NASG) reduce adverse maternal outcomes
from postpartum hemorrhage? Evidence from Egypt and Nigeria. Reprod Health. 2010;7:24.20809942
10
Miller
S
,
Bergel
EF
,
El Ayadi
AM
, et al Non‐pneumatic anti‐shock garment (NASG), a first‐ aid device to decrease maternal
mortality from obstetric hemorrhage: a cluster randomized trial. PLoS One. 2013;8:e76477.24194839
11
Mbaruku
G
,
Therrien
MS
,
Tillya
R
, et al Implementation project of the non‐pneumatic anti‐ shock garment and m‐communication
to enhance maternal health care in rural Tanzania. Reprod Health. 2018;15:177.30340602
12
World Health Organization
. Managing complications in pregnancy and childbirth: a guide for midwives and doctors.
Accessed August 11, 2021. https://apps.who.int/iris/bitstream/handle/10665/255760/9789241565493‐eng.pdf;jsessionid=8D2D1DE3DF5C2CCED6EFCE711D80B804?sequence=1
13
Weeks
A
. The prevention and treatment of postpartum haemorrhage: what do we know, and where
do we go to next?
BJOG. 2015;122:202–210.25289730
14
Hofmeyr
GJ
,
Qureshi
Z
. Preventing deaths due to haemorrhage. Best Pract Res Clin Obstet Gynaecol. 2016;36:68–82.27450867
15
Tunçalp
O
,
Souza
JP
,
Gülmezoglu
M
. World Health Organization. New WHO recommendations on prevention and treatment of
postpartum hemorrhage. Int J Gynecol Obstet. 2013;123:254–256.
16
Lalonde
A
; International Federation of Gynecology and Obstetrics
. Prevention and treatment of postpartum hemorrhage in low‐resource settings. Int
J Gynecol Obstet. 2012;117:108–118.
17
Jordan
K
,
Butrick
E
,
Yamey
G
,
Miller
S
. Barriers and facilitators to scaling up the non‐pneumatic anti‐shock garment for
treating obstetric hemorrhage: a qualitative study. PLoS One. 2016;11:e0150739.26938211
18
Onyewuenyi
A
,
Tilla
R
,
Kinyonge
I
, et al. A qualitative approach to understanding the impact of misuse and misdiagnosis:
Monitoring use of the non‐ pneumatic antishock garment in Tanzania. Annals of Global
Health. 2016;82:489–490.
19
Berdichevsky
K
,
Tucker
C
,
Martínez
A
,
Miller
S
. Acceptance of a new technology for management of obstetric hemorrhage: a qualitative
study from rural Mexico. Health Care Women Int. 2010;31:444–457.20390665
9.2
Uterine balloon tamponade
Despite active management of the third stage of labor, 2%–7% of women experience postpartum
blood loss of more than 500 ml.
1
Uterine balloon tamponade (UBT) is both a diagnostic and therapeutic tool. If bleeding
does not stop after its insertion, then it is better to review the etiology of PPH.
Placement of a UBT device should be considered early when emergency measures for management
of PPH are initiated. It should be performed by competent healthcare providers who
are trained in its insertion to avoid complications that can arise from misplacement.
Perineal, vaginal, and cervical tears and ruptured uterus must be excluded, and the
placenta carefully assessed for completeness to rule out retained fragments of the
placenta. First‐line emergency interventions for atonic PPH include uterine massage,
initiation of large intravenous access, emptying the uterus and bladder, and administration
of oxytocin and TXA (first response bundle). If the uterus fails to contract, ergometrine
or misoprostol should be administered, bimanual uterine or aortic compression should
be initiated, a UBT placed, and the NASG applied (response to refractory PPH bundle).
2
These two sets of approaches have recently been defined as the “PPH bundle”.
3
Observational studies have reported UBT success rates between 83% and 95% overall
with nearly 100% survival among women with uncontrolled hemorrhage when a UBT device
was placed before the onset of advanced shock.
4
,
5
,
6
The integration of UBT into PPH clinical pathways in high‐income countries has been
shown to avert hysterectomy and significantly reduce the need for PPH‐related invasive
procedures such as artery ligation, uterine compression sutures, and arterial embolization.
7
,
8
,
9
,
10
A 2020 systematic review and meta‐analysis showed an overall pooled success rate of
85.9% (95% CI, 83.9–87.9%) for the treatment of PPH, with higher pooled success rates
corresponding to PPH due to uterine atony and placenta previa, and lower pooled success
rates for PPH due to placenta accreta spectrum (PAS) and retained products of conception.
11
A safety trial in Kenya and Sierra Leone on a uniquely designed condom uterine tamponade
device (ESM‐UBT) demonstrated no increased risk of infections or perineal injuries,
and success rates of condom UBT devices appear to be comparable to those of Bakri
balloons.
12
Available UBT devices and specific considerations are described below.
9.2.1
Available UBT devices
Uterine balloon devices can be divided into two groups:
Fixed volume devices: condom uterine balloons (ESM‐UBT kit, CG balloon), Bakri balloon,
Rusch balloon, and Ebb system.
12
,
13
,
14
,
15
,
16
Free flow devices: the glove balloon, Ellavi UBT, and Zukovski balloon.
17
,
18
,
19
The glove and Ellavi balloons allow intrauterine pressure control according to systolic
blood pressure. The Zukovski balloon uses 50 cm (3.8 cmHg) pressure for inflating
the balloon.
9.2.2
Tamponade effect
The mechanism of action of UBT devices is likely multifactorial. Two proposed mechanisms
include device stimulation of receptors, which in turn stimulates uterine contraction,
as well as the direct application of hydrostatic pressure against the bleeding sinuses.
It has been proposed that if uterine wall pressure exerted by a UBT equals the systolic
arterial pressure of the bleeding sinuses, a tamponade effect is created.
14
However, Georgiou
20
measured intraluminal pressures in Bakri balloons in two cases where UBTs had been
placed and discovered that tamponade occurred at UBT device pressures lower than systolic
blood pressures. Further research is needed to better understand the precise biomechanical
relationship between a UBT device and a bleeding uterus.
9.2.3
Free flow tamponade device
Blood is supplied to the uterus via maternal arterial blood that passes through the
myometrium through low resistance sinuses.
21
Following delivery of the placenta, the muscle fibers of the myometrium contract and
retract, closing off the sinuses and limiting blood loss. While the immediate aim
in PPH due to atonic uterus is to arrest blood loss, the ultimate goal is to employ
best practice interventions to facilitate contraction of the myometrium. The surgical
glove balloon, the Ellavi UBT, and the Zukovsky balloon are free flow systems that
allow water to be expelled from the balloon to theoretically better allow for the
natural physiological process of contraction and retraction of the myometrium once
the uterus has recovered.
17
,
18
,
19
However, almost all commercially available UBT devices are low‐pressure, high‐volume
systems that allow for easy UBT expulsion when the uterus regains its tone and begins
to contract.
9.2.4
Drainage port
The need for a drainage port with a UBT device is questionable.
13
,
14
,
16
Drainage ports are only a few millimeters in diameter and therefore are easily obstructed
by clotted blood. Furthermore, since the source of bleeding in atonic uterus is from
the site of placental implantation, which encompasses only about 20% of the uterine
cavity, a drainage port is less likely to be in proximity to the bleeding site.
9.2.5
Correct placement
Multiple techniques have been described on the best approach to place a UBT device.
The approach should in part be determined by the device being used (e.g. stiffness
of the introducing end and number of balloons). To ensure that the balloon could engage
within the area that is actively bleeding, all UBTs should be inserted through the
cervix and positioned to sit in the upper uterine segment. One approach includes placing
the hand into the uterus and ensuring that the fingertips reach the thick anterior
and posterior layers of the upper segment. The UBT is then fed into the upper segment
of the uterus with the free hand. When withdrawing the uterine hand, the tubing is
held with the free hand. While the balloon is filled, two fingers are held in the
vagina below the cervix to prevent inadvertent balloon expulsion.
9.2.6
Assessment of effect
Multiple studies have shown that women with uncontrolled PPH from an atonic uterus
will almost universally survive if a UBT device is placed in a timely fashion. If
UBTs are placed before patients progress to advanced shock, success rates approach
100%.
6
However, studies such as by Dumont et al.
22
and Natarajan et al.
23
have shown that improvised UBTs, delays in recognition of PPH, and lack of action
on actual UBT placement may be barriers to improved outcomes. While different UBT
systems may fill to their desired states at different rates, it is even more important
to recognize that improvised and untested UBTs are less often used. Moreover, whenever
they are, their use is often delayed, they are more difficult to place, fall out more
easily, and are associated with overall lower success rates.
12
,
13
,
14
,
17
,
19
Therefore, immediate recognition of PPH and emergency action with a quality UBT device
is imperative to save lives.
9.2.7
Transfer
Many studies report high rates of hemorrhage control after UBT insertion thus rendering
transfers unnecessary. Most often, incorrect diagnosis and misplacement are the cause
of UBT failure. If bleeding recurs or the patient continues to be unstable after UBT
insertion, then consideration of transfer to higher levels of care should be made.
Transfer can occur with both fixed‐volume balloons and closed‐off free‐flow balloons,
but all UBTs must be carefully secured to prevent accidental displacement. A transfer
plan should be in place in all obstetric settings, regardless of whether it will be
needed or not. This is an absolute necessity in PPH bundles.
9.2.8
UBT after cesarean delivery
Use of UBTs for hemorrhage control after cesarean delivery is a commonly performed
technique worldwide, but there is scant supporting literature. There are a few reports
on successful outcomes with use of UBT in placenta previa. It appears that UBT has
higher success rates in women with PPH after vaginal delivery than after cesarean
delivery.
11
,
18
,
24
,
25
,
26
9.2.9
Combining UBT with compression sutures
Placing a UBT after application of uterine compression sutures requires control of
the amount of pressure exerted in the uterus to prevent uterine necrosis. Although
uterine necrosis is possible following the insertion of compression sutures alone,
the risk understandably would increase with pressure exerted from inside the uterus
when UBT is used additionally. Cases with uterine necrosis following insertion of
compression sutures have been reported with and without UBT.
27
,
28
The surgical glove balloon and the Ellavi UBT are UBT devices that allow the intrauterine
pressure to be controlled by adjusting the height of the intravenous fluid bag or
supply bag above the patient.
17
,
18
With systolic blood pressure of 100 mm Hg and the supply bag or intravenous infusion
fluid 1.3 m above the patient, the pressure exerted by the balloon will be 100 mm Hg.
The specific gravity of mercury is 13 times more than water. The device used for the
balloon must be large enough to be inflated with fluid without requiring any expansion
pressure. This is achieved by using a surgical glove and the Ellavi UBT.
17
,
18
9.2.10
Other uses of UBT
While the use of UBT for uncontrolled PPH is fairly well established, published case
reports and senior leaders in obstetrics and gynecology have described successful
use of UBTs in other circumstances, such as in molar pregnancy‐associated hemorrhage,
placenta accreta, retained placenta, and in cases of intentional vaginal and cervical
placement to temporize uncontrolled bleeding from lacerations.
29
WHO recently published recommendations regarding use of UBT in the context of PPH
due to uterine atony after vaginal birth in women who do not respond to standard first‐line
treatment.
30
According to WHO, among the prerequisites for use of UBT, evidence supports the need
for access to surgical intervention and blood products, as well as the availability
of health personnel skilled in its use. They recognize that conditions may not be
operationalized across all clinical settings and that observational studies suggest
a substantial reduction in the risk of maternal morbidity and mortality following
uterine balloon tamponade, and that further research is needed in low‐resource settings.
BOX 8
FIGO recommends uterine balloon tamponade in the context of refractory PPH.
Uterine balloon tamponade has proven to be an effective nonsurgical technique so that
when employed rapidly by a properly trained person, as the only prerequisite for its
use, it can potentially improve survival in women with PPH.
REFERENCES
1
Begley
CM
,
Gyte
GM
,
Devane
D
,
McGuire
W
,
Weeks
A
. Active versus expectant management for women in the third stage of labour. Cochrane
Database Syst Rev. 2011;(11):CD007412.22071837
2
Escobar
MF
,
Füchtner
CE
,
Carvajal
JA
, et al Experience in the use of non‐pneumatic anti‐ shock garment (NASG) in the management
of postpartum haemorrhage with hypovolemic shock in the Fundación Valle Del Lili,
Cali, Colombia. Reprod Health. 2017;14:58.28499381
3
Althabe
F
,
Therrien
MNS
,
Pingray
V
, et al. Postpartum hemorrhage care bundles to improve adherence to guidelines: a
WHO technical consultation. Int J Gynecol Obstet. 2020;148:290–299.
4
Laas
E
,
Bui
C
,
Popowski
T
,
Mbaku
OM
,
Rozenberg
P
. Trends in the rate of invasive procedures after the addition of the intrauterine
tamponade test to a protocol for management of severe postpartum hemorrhage. Am J
Obstet Gynecol. 2012;207(281):e1–7.
5
Revert
M
,
Cottenet
J
,
Raynal
P
,
Cibot
E
,
Quantin
C
,
Rozenberg
P
. Intrauterine balloon tamponade for management of severe postpartum haemorrhage in
a perinatal network: a prospective cohort study. BJOG. 2017;124:1255–1262.27781401
6
Burke
TF
,
Danso‐Bamfo
S
,
Guha
M
,
Oguttu
M
,
Tarimo
V
,
Nelson
BD
. Shock progression and survival after use of a condom uterine balloon tamponade package
in women with uncontrolled postpartum hemorrhage. Int J Gynecol Obstet. 2017;139:34–38.
7
Gauchotte
E
,
De La Torre
M
,
Perdriolle‐Galet
E
,
Lamy
C
,
Gauchotte
G
,
Morel
O
. Impact of uterine balloon tamponade on the use of invasive procedures in severe
postpartum hemorrhage. Acta Obstet Gynecol Scand. 2017;96(7):877–882.28295136
8
Revert
M
,
Rozenberg
P
,
Cottenet
J
,
Quantin
C
. Intrauterine balloon tamponade for severe postpartum hemorrhage. Obstet Gynecol.
2018;131:143–149.29215522
9
Pendleton
AA
,
Natarajan
A
,
Ahn
R
,
Nelson
BD
,
Eckardt
MJ
,
Burke
TF
. Emergency hysterectomy for uncontrolled postpartum hemorrhage may be averted through
uterine balloon tamponade in Kenya and Senegal. Int J Gynecol Obstet. 2016;133:124.
10
Pendleton
AA
,
Natarajan
A
,
Ahn
R
,
Nelson
BD
,
Eckardt
MJ
,
Burke
TF
. A qualitative assessment of the impact of a uterine balloon tamponade package on
decisions regarding the role of emergency hysterectomy in women with uncontrolled
postpartum haemorrhage in Kenya and Senegal. BMJ Open. 2016;6:e010083.
11
Suarez
S
,
Conde‐Agudelo
A
,
Borovac‐Pinheiro
A
, et al Uterine balloon tamponade for the treatment of postpartum hemorrhage: a systematic
review and meta‐analysis. Am J Obstet Gynecol. 2020;222:293.e1–293.e52.31917139
12
Ramanathan
A
,
Eckardt
MJ
,
Nelson
BD
, et al Safety of a condom uterine balloon tamponade (ESM‐UBT) device for uncontrolled
primary postpartum hemorrhage among facilities in Kenya and Sierra Leone. BMC Pregnancy
Childbirth. 2018;18:168.29764416
13
Mishra
N
,
Agrawal
S
,
Gulabani
K
,
Shrivastava
C
. Use of an innovative condom balloon tamponade in postpartum haemorrhage: a report.
J Obstet Gynaecol India. 2016;66:63–67.26924911
14
Tolosa
JE
,
Bakri
YN
,
Arulkumaran
S
. Intrauterine balloon tamponade for control of postpartum hemorrhage. This topic
last updated: March 12, 2018. Accessed August 25, 2021. https://sniv3r2.github.io/d/topic.htm?path=intrauterine‐balloon‐tamponade‐for‐control‐of‐postpartum‐hemorrhage
15
Georgiou
C
. Balloon tamponade in the management of postpartum haemorrhage: a review. BJOG. 2009;116:748–757.19432563
16
Dildy
GA
,
Belfort
MA
,
Adair
CD
, et al Initial experience with a dual‐balloon catheter for the management of postpartum
hemorrhage. Am J Obstet Gynecol. 2014;210(136):e1–6.24184183
17
Fawcus
S
,
Moodley
J
. A Monograph of the Management of Postpartum Haemorrhage. National Committee for
the Confidential Enquiries into Maternal Deaths in South Africa. National Department
of Health South Africa. 2010.
18
Theron
GB
. Management of postpartum hemorrhage with free‐flow pressure controlled uterine balloon.
Int J Gynecol Obstet. 2018;142:371–373.
19
Usage of the Zhukovsky Balloon Tamponade for PPH Free Flow balloon tamponade
. 2014. Accessed August 25, 2021. http://www.youtube.com/watch?v=qrT8xsuB980
20
Georgiou
C
. Intraluminal pressure readings during the establishment of a positive ‘tamponade
test’ in the management of postpartum haemorrhage. BJOG. 2010;117:295–303.19943825
21
Cronjé
HS
,
Cilliers
JBF
,
du Toit
MA
. Clinical Obstetrics – a Southern African perspective, 4th edn. Van Schaik Publishers;
2016.
22
Dumont
A
,
Bodin
C
,
Hounkpatin
B
, et al Uterine balloon tamponade as an adjunct to misoprostol for the treatment of
uncontrolled postpartum haemorrhage: a randomised controlled trial in Benin and Mali.
BMJ Open. 2017;7:e016590.
23
Natarajan
A
,
Alaska Pendleton
A
,
Nelson
BD
, et al Provider experiences with improvised uterine balloon tamponade for the management
of uncontrolled postpartum hemorrhage in Kenya. Int J Gynecol Obstet. 2016;135:210–213.
24
Cho
HY
,
Park
YW
,
Kim
YH
,
Jung
I
,
Kwon
JY
. Efficacy of intrauterine Bakri balloon tamponade in cesarean section for placenta
previa patients. PLoS One. 2015;10:e0134282.26263014
25
Soyama
H
,
Miyamoto
M
,
Sasa
H
, et al. Effect of routine rapid insertion of Bakri balloon tamponade on reducing
hemorrhage from placenta previa during and after cesarean section. Arch Gynecol Obstet.
2017;296:469–474.28647816
26
Maher
MA
,
Abdelaziz
A
. Comparison between two management protocols for postpartum hemorrhage during cesarean
section in placenta previa: Balloon protocol versus non‐balloon protocol. J Obstet
Gynaecol Res. 2017;43:447–455.27987342
27
Treloar
EJ
,
Anderson
RS
,
Andrews
HS
,
Bailey
JL
. Uterine necrosis following B‐Lynch suture for primary postpartum haemorrhage. BJOG.
2006;113:486–488.16553658
28
Lodhi
W
,
Golara
M
,
Karangaokar
V
,
Yoong
W
. Uterine necrosis following application of combined uterine compression suture with
intrauterine balloon tamponade. J Obstet Gynaecol. 2012;32:30–31.22185530
29
Makin
J
,
Suarez‐Rebling
DI
,
Varma Shivkumar
P
,
Tarimo
V
,
Burke
TF
. Innovative uses of condom uterine balloon tamponade for postpartum hemorrhage in
India and Tanzania. Case Rep Obstet Gynecol. 2018;2018:4952048.29967704
30
World Health Organization
. WHO recommendation on uterine balloon tamponade for the treatment of postpartum
haemorrhage. WHO; 2021. Accessed August 25, 2021. https://apps.who.int/iris/handle/10665/340796
9.3
Uterine artery embolization
Since the first report of the successful use of uterine artery embolization (UAE)
for the treatment of PPH in 1979, success rates have been frequently reported at 90%.
However, unlike the medical and surgical treatments for PPH, no randomized controlled
trials regarding its effectiveness have been conducted. The decision to perform uterine
artery embolization in patients with persistent uterine bleeding should be made in
consultation with an interventional radiologist. Although embolization may be considered
as the technique of choice for managing PPH by some authors, certain practical issues
must be considered.
1
Uterine artery embolization has been shown to be effective in the treatment of various
causes of PPH including placenta accreta: Both UAE and uterine artery ligation have
reported success rates of greater than 90% with low complication rates. If both techniques
are available, embolization is the preferred first choice as it obviates laparotomy.
Ligation can be attempted subsequently if embolization is unsuccessful. In contrast,
after an unsuccessful uterine artery ligation, embolization may be extremely difficult
or even impossible, leaving hysterectomy as the only remaining option. Some cases
may require hysterectomy because of failure of embolization. UAE has shown to be effective
in controlling secondary bleeding and the placenta was found to gradually decrease
in size in all patients. UAE plays an important role in managing these patients because
it is effective at reducing uteroplacental blood flow to further induce thrombosis
of the intervillous space and to achieve necrosis of the retained placental tissue.
2
,
3
,
4
,
5
,
6
,
7
Selective UAE is effective in the control of PPH, thus avoiding hysterectomy.
Availability of resources to perform the procedure: A radiologist trained in embolization
techniques is a prerequisite, as is the appropriate equipment for vascular intervention.
Digital road‐mapping may be required, and the possible complexity means that this
procedure can only be performed in a fully equipped X‐ray department.
8
The interventional radiologist inserts sheaths into both femoral arteries to deploy
a deflated occlusion balloon into each of the internal iliac arteries.
9
The sheaths are removed, and the deflated balloons remain in place until after delivery.
After the patient has undergone a cesarean delivery, the interventional radiologist
will inflate the balloons if needed based on the amount of bleeding. If inflating
the balloons is postponed, the balloons may remain in place for up to a few days until
the patient's providers are certain she will not begin to bleed again; the balloons
can then be removed.
9
UAE has become recognized as a relatively safe technique when preserving the patient's
fertility is a priority
10
,
11
,
12
: Catheterization of the uterine arteries with temporary occlusion by endovascular
balloon is considered a valid option in the management of patients at high risk of
bleeding, in particular those with a pre‐existing diagnosis of placenta accreta in
patients requesting to preserve their uterus. Ojala et al.
13
and Badawy
14
described a series of cases in patients who underwent embolization of the uterine
arteries. Catheterization averted hysterectomy in close to 80% of cases.
9.3.1
Complications
Some studies have documented resumption of menses and even pregnancies after the procedure.
15
Complications of pelvic embolization for PPH occur at a rate of 8.7%. The most common
complication is low‐grade fever. Less common complications are pelvic infection, groin
hematoma, iliac artery perforation, transient buttock ischemia, transient foot ischemia,
and bladder gangrene. Lee et al.
16
listed dissection of the uterine arteries, hematoma at the puncture site, paresthesia,
and lower limb edema as complications.
Currently, most PPH cases requiring hysterectomy are related to placenta previa.
17
. These patients are commonly diagnosed before delivery and are usually delivered
by elective cesarean delivery. This planning may allow increased use of invasive radiological
services in the management of such cases by inserting the intra‐arterial balloons
before going to surgery.
9.3.2
Implementation of treatment
A radiologist trained in embolization techniques is a prerequisite, as is the appropriate
equipment for vascular intervention. Digital road‐mapping may be required, and the
possible complexity means that this procedure can only be performed in a fully equipped
X‐ray department.
8
The obstetrics staff and interventional radiologist select the appropriate operative
procedure (UAE or cesarean hysterectomy) based on the patient's clinical condition
and a refractory response to conservative medical management.
8
UAE is preferred for patients who have a stable systolic and diastolic blood pressure
or heart rate
.
BOX 9
FIGO recommends uterine artery embolization for refractory bleeding uncontrolled by
medical and nonsurgical treatment modalities with the availability of trained personnel
and necessary equipment for using this technology.
REFERENCES
1
Kim
TH
,
Lee
HH
,
Kim
JM
,
Ryu
AL
,
Chung
SH
,
Seok
LW
. Uterine artery embolization for primary postpartum hemorrhage. Iran J Reprod Med.
2013;11:511–518.24639786
2
Ganguli
S
,
Stecker
MS
,
Pyne
D
,
Baum
RA
,
Fan
CM
. Uterine artery embolization in the treatment of postpartum uterine hemorrhage. J
Vasc Interv Radiol. 2011;22:169–176.21183360
3
Bros
S
,
Chabrot
P
,
Kastler
A
, et al Recurrent bleeding within 24 hours after uterine artery embolization for severe
postpartum hemorrhage: are there predictive factors?
Cardiovasc Intervent Radiol. 2012;35:508–514.21614439
4
Hong
TM
,
Tseng
HS
,
Lee
RC
,
Wang
JH
,
Chang
CY
. Uterine artery embolization: an effective treatment for intractable obstetric haemorrhage.
Clin Radiol. 2004;59:96–101.14697382
5
Jung
HN
,
Shin
SW
,
Choi
S‐J
, et al Uterine artery embolization for emergent management of postpartum hemorrhage
associated with placenta accreta. Acta Radiol. 2011;52:638–642.21498276
6
Soyer
P
,
Morel
O
,
Fargeaudou
Y
, et al Value of pelvic embolization in the management of severe postpartum hemorrhage
due to placenta accreta, increta or percreta. Eur J Radiol. 2011;80:729–735.20708361
7
Diop
AN
,
Chabrot
P
,
Bertrand
A
, et al Placenta accreta: management with uterine artery embolization in 17 cases.
J Vasc Interv Radiol. 2010;21:644–648.20227296
8
Wee
L
,
Barron
J
,
Toye
R
. Management of severe postpartum haemorrhage by uterine artery embolization. Br J
Anaesth. 2004;93:591–594.15277301
9
Mahankali
SS
. Interventional radiology: a disruptive innovation which is transforming management
of post‐partum haemorrhage. Journal of Obstetric Anaesthesia and Critical Care. 2017;7:65–68.
10
Angstmann
T
,
Gard
G
,
Harrington
T
,
Ward
E
,
Thomson
A
,
Giles
W
. Surgical management of placenta accreta: a cohort series and suggested approach.
Am J Obstet Gynecol. 2010;202(38):e1–9.
11
Mushtaq
S
,
Kurdi
W
,
Al‐Shammari
M
. Prophylactic catheters placement and intraoperative internal iliac artery embolisation
in a patient with placenta accreta. J Obstet Gynaecol. 2007;27:853–855.18097915
12
Thon
S
,
McLintic
A
,
Wagner
Y
. Prophylactic endovascular placement of internal iliac occlusion balloon catheters
in parturients with placenta accreta: a retrospective case series. Int J Obstet Anesth.
2011;20:64–70.21112764
13
Ojala
K
,
Perälä
J
,
Kariniemi
J
,
Ranta
P
,
Raudaskoski
T
,
Tekay
A
. Arterial embolization and prophylactic catheterization for the treatment for severe
obstetric hemorrhage. Acta Obstet Gynecol Scand. 2005;84:1075–1080.16232175
14
Badawy
SZ
,
Etman
A
,
Singh
M
,
Murphy
K
,
Mayelli
T
,
Philadelphia
M
. Uterine artery embolization: the role in obstetrics and gynecology. Clin Imaging.
2001;25:288–295.11566093
15
Gizzo
S
,
Saccardi
C
,
Patrelli
TS
, et al. Fertility rate and subsequent pregnancy outcomes after conservative surgical
techniques in postpartum hemorrhage: 15 years of literature. Fertil Steril. 2013;99(7):2097–2107.23498891
16
Lee
HY
,
Shin
JH
,
Kim
J
, et al Primary postpartum hemorrhage: outcome of pelvic arterial embolization in
251 patients at a single institution. Radiology. 2012;264:903–909.22829685
17
Gibbins
KJ
,
Einerson
BD
,
Varner
MW
,
Silver
RM
. Placenta previa and maternal hemorrhagic morbidity. J Matern Fetal Neonatal Med.
2018;31(4):494–499.28140723
10
SURGICAL TREATMENT
10.1
Uterine compression sutures for PPH
When a decision is made for surgical intervention, adequate operative theatre should
be set up with adequate anesthesia, surgical and nursing staff, and blood should be
available for transfusion. Upon laparotomy, bleeding at the surgical site should be
minimized by adequate packing to minimize time lost for suturing while active bleeding
is ongoing. In all cases the uterus should be fully exteriorized, if possible. Blood
loss should be minimized while fully extending the uterus, causing vasoconstriction
and a tourniquet placed around the low segment until surgical compression sutures
are successfully applied.
1
This enables the surgical team to use the following described methods by applying
the uterine compression sutures with a high degree of safety. In addition, injections
of vasopressin at a dose of 4 U in 20 ml of saline in the placental bed after removal
of the placenta may lead to reduced blood loss as well.
2
Placement of endouterine square hemostatic sutures may also be used to control bleeding
from the placental bed.
3
Hemostatic suturing technique as a second‐line strategy for control of uterine bleeding
due to uterine atony is an effortless, fast, and conservative surgical procedure.
It can be performed satisfactorily after a cesarean delivery or after a vaginal delivery.
4
Complications related to its application have been identified but there are no reports
of deaths related to compression sutures. Complications can include uterine synechia
or ischemia, uterine necrosis,
5
intrauterine infection,
6
and strangulation of the intestinal loop and abdominal omentum when nonabsorbable
stitches are used,
7
but nonabsorbable sutures can be used if other types of sutures are not available.
While most births are uncomplicated, obstetricians are often faced with PPH at the
time of vaginal or cesarean delivery.
8
,
9
If initial management with fundal massage, manual uterine compression, or uterotonics
(oxytocin, misoprostol, methergine, or carboprost tromethamine) does not adequately
reduce bleeding, placement of compression sutures can be done to slow bleeding and
stabilize the patient, avoid hysterectomy, and ultimately reduce maternal morbidity
or death. The three most used compression suture techniques for PPH are B‐Lynch,
10
Hayman,
11
and Pereira.
12
Other compression sutures are cited in the literature, such as Cho, Ouahba, Hackethal,
and Massuba.
8
If a Bakri balloon is available, the obstetrician can combine any of these three compression
sutures with the placement of the balloon to tamponade bleeding. In some instances,
expedient placement of an O’Leary stitch for temporary devascularization of the uterine
arteries can decrease bleeding and allow additional time for placement of the compression
sutures. As with the conduct of cesarean delivery, specific practical issues have
to be considered. First, the obstetrician should be well versed in sterile pelvic
vascular operative techniques, as placement of sutures will occur at the time of cesarean
delivery or with laparotomy following vaginal delivery and PPH. Second, since time
is critical to reducing maternal blood loss, an operative team with the technical
skills for additional anesthesia, administration of blood products, and surgical assistance
is crucial to the success of surgical management. Three commonly used compression
sutures are described below and existing data are summarized on the effectiveness
of each compression technique.
10.1.1
Commonly used compression sutures for managing PPH
The B‐Lynch suture was first introduced in 1997 by Christopher Lynch to address hemorrhage
with open hysterotomy at the time of cesarean delivery.
10
A suture is placed on the right side of the hysterotomy, entering at the base of the
incision and exiting at the top.
13
The suture is then carried across the top of the right fundus and a posterior stitch
is placed, with the entrance of the suture at the same level of the anterior suture
and exiting on the left posterior side of the uterus at the level of the uterine incision.
Suture is then looped over the left fundus, and another stitch is placed at the top
of the left side of the uterine incision and exiting at the base of the incision.
The suture is then tugged tightly, compressing the body of the uterus with placement
of a surgeon's knot. Following placement of the B‐Lynch suture, the transverse hysterotomy
is closed in the usual fashion. In the original description of B‐Lynch, a chromic
suture was used. Subsequent case studies have reported successful use of a monocryl
suture.
Additional options for compression sutures include the Hayman and Pereira. In 2002,
the Hayman suture was designed to be a technically easier alternative to the B‐Lynch
suture that could be placed expediently and not require hysterotomy. The steps for
placing a Hayman suture include two to four longitudinal (on the left and right side
of the uterus) sutures that pass directly from the anterior uterine wall and through
the posterior uterine wall and are tied using a surgeon's knot at the fundus. A transverse
cervicoisthmic suture traversing the anterior and posterior uterine walls can be placed
to address bleeding from the lower uterine segment.
The Pereira compression technique includes five sutures, combining two longitudinal
sutures with three transverse sutures. The advantage of the Pereira sutures is that
placement occurs in the submucosal region and avoids the endometrial cavity. However,
attention is needed for correct placement of the transverse sutures to prevent damage
to the uterine vessels and ureters.
Based on the available literature, the success rate of compression sutures in achieving
hemostasis is 76%–100%.
14
To date, no randomized controlled trials or controlled studies have compared the efficacy
of the different compression sutures. In the three original studies for B‐Lynch, Hayman,
and Pereira, success rates were reported as 100% (5/5 for B‐Lynch, 3/3 for Hayman,
and 7/7 for Pereira). In a systematic review,
14
the overall success rate of compression sutures was reported as 91.7%. Given the broad
use of compression sutures and the impact on maternal morbidity and mortality, it
is unlikely that a randomized controlled trial to compare the efficacy of different
compression techniques will be conducted. However, an observational study comparing
the effectiveness of different compression sutures on estimated blood loss and measures
of maternal morbidity is an obvious next step to move the literature forward.
BOX 10
FIGO recommends compression sutures as one of the options to control PPH when medical
and nonsurgical treatment modalities fail.
REFERENCES
1
Huijgen
QCA
,
Gijsen
AF
,
Hink
E
,
Van Kesteren
PJM
. Cervical tourniquet in case of uncontrollable haemorrhage during caesarean section
owing to a placenta accreta. Case Reports. 2013;2013(apr22 1):bcr2013009237.
2
Kato
S
,
Tanabe
A
,
Kanki
K
, et al Local injection of vasopressin reduces the blood loss during cesarean section
in placenta previa. J Obstet Gynaecol Res. 2014;40:1249–1256.24750470
3
Arduini
M
,
Epicoco
G
,
Clerici
G
,
Bottaccioli
E
,
Arena
S
,
Affronti
G
. B‐Lynch suture, intrauterine balloon, and endouterine hemostatic suture for the
management of postpartum hemorrhage due to placenta previa accreta. Int J Gynecol
Obstet. 2010;108(3):191–193.
4
Kayem
G
,
Kurinczuk
JJ
,
Alfirevic
Z
,
Spark
P
,
Brocklehurst
P
,
Knight
M
. Specific second‐line therapies for postpartum haemorrhage: a national cohort study.
BJOG. 2011;118:856–864.21392247
5
Joshi
VM
,
Shrivastava
M
. Partial ischemic necrosis of the uterus following a uterine brace compression suture.
BJOG. 2004;111:279–280.14961893
6
Ochoa
M
,
Allaire
AD
,
Stitely
ML
. Pyometria after hemostatic square suture technique. Obstet Gynecol. 2002;99:506–509.11864682
7
Wu
HH
,
Yeh
GP
. Uterine cavity synechiae after hemostatic square suturing technique. Obstet Gynecol.
2005;105(5 Pt 2):1176–1178.15863572
8
Mousa
HA
,
Blum
J
,
Abou El Senoun
G
,
Shakur
H
,
Alfirevic
Z
. Treatment for primary postpartum haemorrhage. Cochrane Database Syst Rev. 2014;(2):CD003249.24523225
9
Cunningham
FG
,
Leveno
KJ
,
Bloom
SL
, et al. Williams Obstetrics, 23rd edn. McGrawHill; 2010.
10
B‐Lynch
C
,
Coker
A
,
Lawal
AH
,
Abu
J
,
Cowen
MJ
. The B‐Lynch surgical technique for the control of massive postpartum haemorrhage:
an alternative to hysterectomy? Five cases reported. Br J Obstet Gynaecol. 1997;104:372–375.9091019
11
Hayman
RG
,
Arulkumaran
S
,
Steer
PJ
. Uterine compression sutures: surgical management of postpartum hemorrhage. Obstet
Gynecol. 2002;99:502–506.11864681
12
Pereira
A
,
Nunes
F
,
Pedroso
S
,
Saraiva
J
,
Retto
H
,
Meirinho
M
. Compressive uterine sutures to treat postpartum bleeding secondary to uterine atony.
Obstet Gynecol. 2005;106:569–572.16135589
13
Price
N
,
B‐Lynch
C
. Technical description of the B‐Lynch brace suture for treatment of massive postpartum
hemorrhage and review of published cases. Int J Fertil Womens Med. 2005;50:148–163.16405100
14
Doumouchtsis
SK
,
Papageorghiou
AT
,
Arulkumaran
S
. Systematic review of conservative management of postpartum hemorrhage: what to do
when medical treatment fails. Obstet Gynecol Surv. 2007;62:540–547.17634155
10.2
Uterine artery ligation
Uterine artery ligation has been described for the control of PPH since 1960; it is
considered a simple, fast‐performing technique
1
and one of the most popular fertility‐preserving surgical techniques.
2
It is an effective management strategy for bleeding control with success rates of
42% and 88% described.
3
,
4
,
5
,
6
The recent evidence on the effectiveness of uterine artery ligation to control bleeding
in PPH is centered on case reports, mainly associated with other techniques and with
the use of tranexamic acid.
7
,
8
,
9
,
10
,
11
The success rates for the procedure are higher depending on the time of the intervention
from the beginning of the bleeding, the presence of coagulopathy, and the expertise
of the surgeons.
12
,
13
The latest Cochrane systematic review of mechanical and surgical interventions for
treating primary PPH found no controlled clinical trials evaluating its effectiveness
for uterine artery ligation.,
14
BOX 11
FIGO recommends uterine artery ligation as one of the options to rapidly control PPH
when medical, nonsurgical approaches, and compression sutures fail.
REFERENCES
1
O'Leary
JL
,
O'Leary
JA
. Uterine artery ligation in the control of intractable postpartum hemorrhage. Am
J Obstet Gynecol. 1966;94(7):920–924.5295587
2
Verit
FF
,
Çetin
O
,
Keskin
S
,
Akyol
H
,
Zebitay
AG
. Does bilateral uterine artery ligation have negative effects on ovarian reserve
markers and ovarian artery blood flow in women with postpartum hemorrhage?
Clin Exp Reprod Med. 2019;46(1):30–35.30827075
3
Joshi
VM
,
Otiv
SR
,
Majumder
R
,
Nikam
YA
,
Shrivastava
M
. Internal iliac artery ligation for arresting postpartum haemorrhage. BJOG. 2007;114:356–361.17261120
4
Papp
Z
,
Tóth‐Pál
E
,
Papp
C
, et al. Hypogastric artery ligation for intractable pelvic hemorrhage. Int J Gynecol
Obstet. 2006;92(1):27–31.
5
Ledee
N
,
Ville
Y
,
Musset
D
,
Mercier
F
,
Frydman
R
,
Fernandez
H
. Management in intractable obstetric haemorrhage: an audit study on 61 cases. Eur
J Obstet Gynecol Reprod Biol. 2001;94:189–196.11165724
6
Unal
O
,
Kars
B
,
Buyukbayrak
EE
,
Karsidag
AY
,
Turan
C
. The effectiveness of bilateral hypogastric artery ligation for obstetric hemorrhage
in three different underlying conditions and its impact on future fertility. J Matern
Fetal Neonatal Med. 2011;24:1273–1276.21557692
7
Abbas
AM
,
Shady
NW
,
Sallam
HF
. Bilateral uterine artery ligation plus intravenous tranexamic acid during cesarean
delivery for placenta previa: a randomized double‐blind controlled trial. J Gynecol
Obstet Hum Reprod. 2019;48(2):115–119.30412786
8
Kaya
B
,
Tuten
A
,
Daglar
K
, et al B‐Lynch uterine compression sutures in the conservative surgical management
of uterine atony. Arch Gynecol Obstet. 2015;291(5):1005–1014.25315382
9
Kaya
B
,
Tuten
A
,
Daglar
K
, et al Balloon tamponade for the management of postpartum uterine hemorrhage. J Perinat
Med. 2014;42(6):745–753.24663227
10
Danisman
N
,
Kahyaoglu
S
,
Celen
S
, et al. The outcomes of surgical treatment modalities to decrease "near miss" maternal
morbidity caused by peripartum hemorrhage. Eur Rev Med Pharmacol Sci. 2014;18(7):1092–1097.24763892
11
Kaya
B
,
Damarer
Z
,
Daglar
K
,
Unal
O
,
Soliman
A
,
Guralp
O
. Is there yet a role for internal iliac artery ligation in obstetric hemorrhage with
the current gain in popularity of other uterus sparing techniques?
J Matern Fetal Neonatal Med. 2017;30(11):1325–1332.27405790
12
American College of Obstetricians and Gynecologists
. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician‐Gynecologists
Number 76, October 2006: postpartum hemorrhage. Obstet Gynecol. 2006;108(4):1039–1047.17012482
13
Vanwinkel
S
,
Claes
L
,
Van den Bosch
T
. Obstetrical outcome after B‐Lynch sutures and ligation of uterine arteries: a case
report. Case Rep Womens Health. 2021;30:e00303.33777709
14
Kellie
FJ
,
Wandabwa
JN
,
Mousa
HA
,
Weeks
AD
. Mechanical and surgical interventions for treating primary postpartum haemorrhage.
Cochrane Database Syst Rev. 2020;(7):CD013663.32609374
10.3
Bilateral internal iliac artery ligation
Internal iliac artery ligation was first performed by Kelly in 1894,
1
with reported success rates between 40% and 100%.
2
,
3
It reduces pelvic blood flow by half and pulse pressure by 85%, thereby simulating
a venous rather than an arterial circulation, and promoting hemostasis.
1
,
2
Although this technique provides a rapid and effective way to control hemorrhage,
it remains underused because of understandable fear of injury to surrounding structures:
internal and external iliac arteries and ureters
2
,
4
and should only be considered if experienced pelvic surgeons are available. Internal
iliac artery ligation may avoid the need for hysterectomy in the context of uterine
atony.
2
In addition, in cases of traumatic PPH such as uterine rupture and extensive genital
injuries, internal artery ligation clears the operative field and facilitates hysterectomy.
2
During the procedure, the common iliac artery is identified. After dissection, the
ureter is visualized crossing the common iliac artery at its bifurcation. The common
iliac artery branches into an internal iliac (hypogastric) artery, coursing medially
and inferiorly, and the external iliac artery coursing laterally and superiorly. The
arteries are not infrequently adherent to the underlying veins and require appropriate
dissection.
5
With right‐angled forceps a suture is introduced between the artery and the vein,
and a knot is made.
4
,
5
Noteworthy is that even after bilateral internal iliac artery ligation, the vascular
supply to the pelvis is not completely compromised due to the extensive collateral
circulation that exists.
4
,
5
The revascularization is provided by the deep femoral artery, the anastomosis between
the medial femoral circumflex and obturator artery, and that between the lateral femoral
circumflex and superior gluteal artery, and the ovarian artery.
4
,
5
Obstetricians ought to be more familiar with this procedure as it is an effective
and rapid way to control PPH.
BOX 12
FIGO recommends internal iliac artery ligation as one of the options to rapidly control
PPH for management of PPH when medical, nonsurgical approaches, and compression sutures
fail.
FIGO also recommends that all obstetricians familiarize themselves with the internal
iliac artery location and with the technique of its ligation.
REFERENCES
1
Burchell
RC
. Physiology of internal iliac artery ligation. J Obstet Gynaecol Br Commonw. 1968;75:642–651.5659060
2
Joshi
VM
,
Otiv
SR
,
Majumder
R
,
Nikam
YA
,
Shrivastava
M
. Internal iliac artery ligation for arresting postpartum haemorrhage. BJOG. 2007;114:356–361.17261120
3
Wang
CY
,
Pan
HH
,
Chang
CC
,
Lin
CK
. Outcomes of hypogastric artery ligation and transcatheter uterine artery embolization
in women with postpartum hemorrhage. Taiwan J Obstet Gynecol. 2019;58:72–76.30638485
4
Selçuk
İ
,
Uzuner
B
,
Boduç
E
,
Baykuş
Y
,
Akar
B
,
Güngör
T
. Step‐by‐step ligation of the internal iliac artery. J Turk Ger Gynecol Assoc. 2019;20:123–128.30499283
5
B‐Lynch
C
,
Keith
LG
,
Campbell
WB
. Internal iliac (hypogastric) artery ligation. In:
Arulkumaran
S
,
Karoshi
M
,
Keith
LG
,
Lalonde
AB
,
B‐Lynch
C
. eds. A Comprehensive Textbook of Postpartum Hemorrhage, 2nd edn. Sapiens Publishing;
2012:441–447.
10.4
Hysterectomy
Peripartum hysterectomy is performed in the treatment of PPH when all other conventional
methods fail to control the bleeding.
1
The prevalence is higher in low‐income regions than in high‐income regions (2.8 and
0.7 per 1000 deliveries, respectively).
2
The incidence of this procedure has been on the rise, increasing by 15% in the USA
between 1994 and 2007.
3
Similarly, in Turkey, the rate has increased from 0.03% in 2000–2006 to 0.07% in 2007–2013.
In most of the studies, this was attributed to the increased rates of cesarean delivery.
1
,
2
,
3
,
4
,
5
The most common indications for peripartum hysterectomy are placental pathology such
as abnormal placentation, placenta previa, and placental abruption (38%), uterine
atony (27%), and uterine rupture (26%).
2
Peripartum hysterectomy is associated with high rates of maternal morbidity and complications
due to the need for blood transfusions, coagulation disorders, injury to the urinary
tract, the need for re‐exploration in case of persistent bleeding, and postoperative
fever.
1
The maternal mortality rate varies according to countries, ranging from 0% in Turkey,
6
the UK,
7
and New Zealand,
8
to 3.2% in Australia,
9
and as high as 11.8% in Nigeria.,
10
BOX 13
FIGO recommends abdominal hysterectomy as treatment for PPH when all other medical,
nonsurgical, and surgical treatment modalities have failed to control PPH.
Care must be taken to have adequate blood supplies. Subtotal hysterectomy can shorten
the procedure and is important in a hemodynamically unstable patient.
REFERENCES
1
Demirci
O
,
Tuğrul
AS
,
Yilmaz
E
,
Tosun
Ö
,
Demirci
E
,
Eren
YS
. Emergency peripartum hysterectomy in a tertiary obstetric center: nine years evaluation.
J Obstet Gynaecol Res. 2011;37:1054–1060.21481094
2
Van den Akker
T
,
Brobbel
C
,
Dekkers
OM
,
Bloemenkamp
KW
. Prevalence, indications, risk indicators, and outcomes of emergency peripartum hysterectomy
worldwide: a systematic review and meta‐analysis. Obstet Gynecol. 2016;128:1281–1294.27824773
3
Bateman
BT
,
Mhyre
JM
,
Callaghan
WM
,
Kuklina
EV
. Peripartum hysterectomy in the United States: nationwide 14 year experience. Am
J Obstet Gynecol. 2012;206(63):e1–8.
4
Temizkan
O
,
Angın
D
,
Karakuş
R
,
Şanverdi
İ
,
Polat
M
,
Karateke
A
. Changing trends in emergency peripartum hysterectomy in a tertiary obstetric center
in Turkey during 2000–2013. J Turk Ger Gynecol Assoc. 2016;17:26–34.27026776
5
Chawla
J
,
Arora
D
,
Paul
M
,
Ajmani
SN
. Emergency obstetric hysterectomy: a retrospective study from a Teaching Hospital
in North India over eight years. Oman Med J. 2015;30:181–186.26171124
6
Danisman
N
,
Baser
E
,
Togrul
C
,
Kaymak
O
,
Tandogan
M
,
Gungor
T
. Emergency peripartum hysterectomy: experience of a major referral hospital in Ankara.
Turkey. J Obstet Gynaecol. 2015;35:19–21.24999814
7
Jones
B
,
Zhang
E
,
Alzouebi
A
, et al Maternal and perinatal outcomes following peripartum hysterectomy from a single
tertiary centre. Aust N Z J Obstet Gynaecol. 2013;53:561–565.24138323
8
Wong
TY
. Emergency peripartum hysterectomy: a 10‐year review in a tertiary obstetric hospital.
N Z Med J. 2011;124:34–39.
9
Awan
N
,
Bennett
MJ
,
Walters
WA
. Emergency peripartum hysterectomy: a 10‐year review at the Royal Hospital for Women,
Sydney. Aust N Z J Obstet Gynaecol. 2011;51:210–215.21631438
10
Akintayo
AA
,
Olagbuji
BN
,
Aderoba
AK
,
Akadiri
O
,
Olofinbiyi
BA
,
Bakare
B
. Emergency peripartum hysterectomy: a multicenter study of incidence, indications
and outcomes in Southwestern Nigeria. Matern Child Health J. 2016;20:1230–1236.26961244
11
ASSESSMENT AND RESUSCITATION
11.1
Damage control resuscitation in PPH
Hemorrhagic shock is the most frequent type of shock in obstetric patients.
1
Blood loss exceeding 40% of total blood volume leads to global hypoxia and metabolic
acidosis.
2
These metabolic complications, accompanied by organ hypoperfusion, trigger an irreversible
state of coagulopathy, bolstering hemorrhage and inducing multiple organ dysfunction
and death.
3
The concept of damage control resuscitation (DCR) was first reported by trauma surgeons
and its applicability has spread in traumatic and nontraumatic scenarios in general
surgery, orthopedics, and obstetrics.
4
DCR consists of a series of strategies to minimize hemorrhage, prevent the deadly
triad (coagulopathy, acidosis, and hypothermia), and maximize tissue oxygenation.
This is achieved by a staged surgical approach that minimizes operative time, counteracting
life‐threatening conditions and deferring the definitive surgical procedures until
normal physiology is restored at the intensive care unit (ICU).
5
,
6
,
7
Efforts in DCR are focused on permissive resuscitation by blood product transfusion,
use of massive blood transfusion protocols, limited use of crystalloids, bleeding
control (including damage control surgery [DCS] and damage control interventional
radiology [DCIR]), and physiological and biochemical stabilization in the ICU.
4
,
5
,
6
DCR is usually reserved for severely injured patients who may not survive the surgical
efforts to achieve primary repair in the operating room.
4
It is evident that this approach can be considered only in higher‐level care facilities
where there is availability of experienced personnel with 24‐h laboratory and blood
bank services.
The most important aspects of DCS are described below. Hypotensive and hemostatic
reanimation are discussed in sections 11.2.1 and 11.2.6, respectively.
11.1.1
Decision for damage control surgery
Physiological and metabolic markers have been proposed to identify patients that could
benefit from DCS.
4
Three parameters have been described in the literature as significant clinical indicators
for early implementation of DCR and DCS
8
: acidosis (base deficit >8), blood loss >1500 ml, and hypothermia (temperature <35°C).
Other important parameters to consider are systolic blood pressure <70 mm Hg, maternal
blood pH <7.1, and persistent bleeding despite several transfusions (defined as 6
units of packed red blood cells by some authors
7
and >10 units by others
4
) (Table 9).
TABLE 9
Alternative indications for damage control surgery secondary to postpartum hemorrhage
a
Indication
Systolic blood pressure <70 mm Hg
Body temperature <34ºC
Maternal blood pH <7.1
Venous bleeding not suitable for surgical control
Persistent bleeding despite several transfusions of blood products (>10 units of PRBC)
Massive transfusion: 6 units of Red Blood Cells (during the first 4 h)
Increasing and continuous need for fluids due to active nonarterial bleeding
Hemodynamic instability, requiring persistent vasopressor support or that results
in the development of ventricular arrhythmias
Coagulopathy resulting from a combination of hypothermia (temperature <35°C), acidosis
(pH <7.3), and loss of coagulation factors
Duration of surgery >90 min
a
Source: Carvajal et al. [4] and Pacheco et al. [7]. Adapted with permission.
John Wiley & Sons, Ltd
Continuous vital sign monitoring and serial monitoring with blood gas analysis and
body temperature are recommended. Operative time and number of blood units transfused
are also crucial for DCR decision‐making.
4
11.1.2
Bleeding control
After identifying eligible DCS patients, when medical and surgical conservative measures
to control bleeding fail, a sequential four‐phase approach should be performed.
4
Initial laparotomy
The primary objective is hemorrhage control, which is achieved by an abdominal hysterectomy.
The type of hysterectomy to be performed depends on the preference and expertise of
the operator and the clinical condition of the patient; other factors such as age,
cause of hemorrhage, hemodynamic stability, and pelvic anatomy must be considered.
9
According to several studies, there are no statistically significant differences between
total and subtotal hysterectomy in terms of complications, blood transfusions, and
ICU admission.
9
,
10
,
11
Subtotal hysterectomy has been associated with quicker hemorrhage control and shorter
operative times, hence is the preferred approach over total hysterectomy.
9
,
11
The bleeding site must be identified to pick the most suitable approach. When the
bleeding is in the lower uterine segment, cervix, or vaginal fornices, a subtotal
hysterectomy may not be the most effective approach for hemorrhage control since the
arterial circulation of the cervix has a high blood flow rate and could cause bleeding
persistence. In these cases, total hysterectomy is preferred.
9
,
10
Operative time is a crucial determinant in patient survival. Prolonged operative time
has been linked to adverse outcomes as it can institute an irreversible physiologic
insult; thus, the need to keep operative time under 90 min.
4
As in other surgical specialties, packing is the cornerstone of obstetric DCS.
4
,
7
Pelvic packing should be performed with at least 7–10 compresses, according to reported
experience.
2
,
12
Aside from pelvic packing, temporary abdominal closure is performed alongside, as
a complementary feature of the procedure. The latter can be achieved using a negative
pressure system like vacuum pack or partial closure with a Viaflex bag (Bogota Bag)
without the need for negative pressure.
2
,
12
Currently, there is neither consensus nor sufficient evidence regarding the use of
prophylactic antibiotics in patients undergoing DCS with abdominal packing.
4
Several surgical guidelines recommend the administration of a single preoperative
dose of broad‐spectrum antibiotics, which theoretically should provide sufficient
coverage for aerobic and anaerobic microorganisms.
4
,
13
,
14
Other experts suggest administration of prophylactic broad‐spectrum antibiotics every
6–8 h until the abdominal packing is removed. Nevertheless, further studies are necessary
to provide evidence‐based recommendations in the obstetric population.
7
Resuscitation – ICU
At this stage, the patient must be transferred to the ICU to address the physiologic
derangements of the hemorrhagic patient: coagulation disorders and metabolic abnormalities.
6
Interdisciplinary care involving the obstetrician and critical care specialist is
key for these patients as complications could arise at any time.
4
It is crucial to accurately quantify the accumulation of blood in the abdominal cavity.
The optimal device to do so, after partial abdominal closure, is the vacuum pack,
which allows a more precise quantification of bleeding during the postoperative period.
In patients without coagulopathy, the drainage of >400 ml/h of blood through the vacuum
pack represents an early indication for laparotomy.
4
Definitive surgery
After restoring normal physiology, it is considered safe to review the abdominal cavity.
Ideally, this should be performed 48–72 h after the initial surgical procedure.
4
Patients may require one or more surgical interventions, depending on the operative
findings. In cases where further interventions are warranted, it is recommended to
continue with techniques of temporary closure of the abdominal cavity.
15
Definitive closure of abdominal wall and cavity
The final stage is the definitive closure of the abdominal wall, which is performed
after all surgeries have been successfully completed and all additional damage has
been repaired.
4
11.1.3
Complications
The majority of DCS complications depend on the time of closure of the abdominal fascia.
It is important to consider that the number of reinterventions is directly related
to a higher percentage of infectious complications, wound dehiscence, and abdominal
wall closure problems.
16
The main complications include infection of the surgical wound in 28% of cases, presence
of intra‐abdominal collections in 20%, and evisceration in 10% of patients.
2
Implementation of prophylactic antibiotic therapy could counteract these complications,
as it targets the polybacterial flora present in the female genital tract. An interdisciplinary
approach could be required in case of complications derived from injuries secondary
to the surgical procedure such as urinomas, perforations, or fistulas, among others.
17
11.1.4
Final objectives in resuscitation
DCR should be maintained as long as there are signs of bleeding and coagulopathy.
A continuous assessment of the hemodynamic and physiological status of the patient
is required. Monitoring several resuscitation parameters is essential until tissue
hypoxia reverts. These parameters include pH, base deficit, lactate, hematocrit, and
coagulation—ideally evaluated with conventional laboratory tests and point‐of‐care
testing (POCT) of viscoelastic coagulation such as thromboelastography (TEG) and rotational
thromboelastometry (ROTEM). In patients with a clinical trend toward improvement,
the decision to perform definitive surgery is appropriate.,
4
BOX 14
FIGO recommends that damage control resuscitation (DCR) should be implemented in the
management algorithms for major obstetric hemorrhage.
All countries should establish one or more referral hospital(s) and develop expert
teams that are familiar with this strategy, the technique, and indications to be able
to offer DCR.
REFERENCES
1
Pacheco
LD
,
Saade
GR
,
Gei
AF
,
Hankins
GD
. Cutting‐edge advances in the medical management of obstetrical hemorrhage. Am J
Obstet Gynecol. 2011;205:526–532.21816382
2
Ordóñez
CA
,
Nieto
AJ
,
Carvajal
JA
, et al Damage control surgery for the management of major obstetric hemorrhage: experience
from the Fundación Valle del Lili, Cali, Colombia. Panamerican Journal of Trauma,
Critical Care and Emergency Surgery. 2017;6:1–7.
3
Clark
SL
,
Hankins
GD
. Preventing maternal death: 10 clinical diamonds. Obstet Gynecol. 2012;119(2 Pt 1):360–364.22270288
4
Carvajal
JA
,
Ramos
I
,
Kusanovic
JP
,
Escobar
MF
. Damage‐control resuscitation in obstetrics. J Matern Fetal Neonatal Med. 2022;35:785–798.
5
Bogert
JN
,
Harvin
JA
,
Cotton
BA
. Damage control resuscitation. J Intensive Care Med. 2016;31:177–186.25385695
6
West
N
,
Dawes
R
. Trauma resuscitation and the damage control approach. Surgery. 2018;36:409–416.
7
Pacheco
LD
,
Lozada
MJ
,
Saade
GR
,
Hankins
GDV
. Damage‐control surgery for obstetric hemorrhage. Obstet Gynecol. 2018;132:423–427.29995745
8
Ordoñez
CA
,
Badiel
M
,
Pino
LF
, et al Damage control resuscitation: Early decision strategies in abdominal gunshot
wounds using an easy “ABCD” mnemonic. J Trauma Acute Care Surg. 2012;73:1074–1078.23117373
9
Gungor
T
,
Simsek
A
,
Ozdemir
AO
,
Pektas
M
,
Danisman
N
,
Mollamahmutoglu
L
. Surgical treatment of intractable postpartum hemorrhage and changing trends in modern
obstetric perspective. Arch Gynecol Obstet. 2009;280:351–355.19130066
10
Mukherjee
S
,
Arulkumaran
S
. Post‐partum haemorrhage. Obstet Gynaecol Reprod Med. 2009;19:121–126.
11
Zhang
Y
,
Yan
J
,
Han
Q
, et al Emergency obstetric hysterectomy for life‐threatening postpartum hemorrhage:
a 12‐year review. Medicine. 2017;96:e8443.29137030
12
Escobar
MF
,
García
A
,
Fonseca
J
,
Herrera
E
,
Guerrero
JE
. Cirugía de control de daños: un concepto aplicable en ginecología y obstetricia.
Colombia Médica. 2005;36:110–114.
13
Goldberg
SR
,
Anand
RJ
,
Como
JJ
, et al Prophylactic antibiotic use in penetrating abdominal trauma: an Eastern Association
for the Surgery of Trauma practice management guideline. J Trauma Acute Care Surg.
2012;73(5 Suppl 4):S321–S325.23114488
14
Godat
L
,
Kobayashi
L
,
Costantini
T
,
Coimbra
R
. Abdominal damage control surgery and reconstruction: world society of emergency
surgery position paper. World J Emerg Surg. 2013;8:53.24341602
15
Griggs
C
,
Butler
K
. Damage control and the open abdomen: challenges for the nonsurgical intensivist.
J Intensive Care Med. 2016;31:567–576.26180038
16
Kirkpatrick
AW
,
Roberts
DJ
,
De Waele
J
, et al Intra‐abdominal hypertension and the abdominal compartment syndrome: updated
consensus definitions and clinical practice guidelines from the World Society of the
Abdominal Compartment Syndrome. Intensive Care Med. 2013;39:1190–1206.23673399
17
Burlew
CC
. The open abdomen: practical implications for the practicing surgeon. Am J Surg.
2012;204:826–835.23000185
11.2
Resuscitation
Once the shock has occurred in PPH, it is estimated that the mortality of patients
will increase dramatically.
3
,
4
,
5
To mitigate metabolic complications, strategies such as hypotensive fluid resuscitation
and transfusion protocols have been studied for hemostatic reanimation.
There are two strategies for fluid resuscitation in patients with hemorrhage: the
aggressive approach and the hypotensive resuscitation approach. Aggressive resuscitation
refers to the traditionally used strategy in which the key principle is restoring
the effective circulating blood volume, and rapid normalizing of blood pressure with
administration of large amounts of crystalloids.
4
,
6
Hypotensive resuscitation, also called permissive hypotension, consists of restrictive
crystalloid resuscitation during the early stages of a hemorrhagic shock to maintain
lower than normal systolic or mean blood pressure, sustaining organ perfusion until
control of the bleeding occurs.
4
,
7
In contrast, hemostatic reanimation is based on early and aggressive blood product
replacement, transfusing red blood cells (PRBC), fresh frozen plasma (FFP), and platelets
(PLT) in the same proportion as found in circulating blood to correct coagulopathy.
8
,
9
,
10
Hypotensive resuscitation and hemostatic reanimation are the fundamentals for DCR.
11
,
12
11.2.1
Hypotensive resuscitation
The concept of hypotensive resuscitation is because administering small crystalloid
volumes reduces the risk of dilutional coagulopathy and maintaining a lower blood
pressure is less likely to disintegrate the pre‐formed blood clots. Aggressive resuscitation
may worsen coagulopathy and hemorrhage by increasing intravascular hydrostatic pressures,
diluting coagulation factors, and inducing more hypothermia, which results in deterioration
of the triad of death.
19
,
6
,
12
Furthermore, an excessive rise in blood pressure could also result in higher red blood
cell loss leading to more hypoxia and acidosis in tissues.
19
,
6
11.2.2
Intravenous fluids
Among the initial strategies for reanimation, the administration of crystalloids in
small boluses of 500 ml is recommended.
10
Scientific evidence recommends the use of balanced crystalloid solutions such as Ringer's
lactate owing to the risk of hyperchloremic acidosis and the worsening of kidney function
with chlorine‐rich fluids (saline solution).
7
This is particularly important for LMICs, where saline‐based solutions are in abundance.
After the administration of each bolus, physicians must assess the clinical status
of patients, looking for an improvement in signs and symptoms of shock resulting from
blood loss.
10
11.2.3
Targeted blood pressure
The difference between aggressive and hypotensive resuscitation lies within targeted
blood pressure management.
4
Mean arterial pressure (MAP) represents the perfusion of the majority of organs, therefore
providing the target for clinicians to guide fluid administration.
11
Hemorrhagic shock animal models have demonstrated a positive benefit in survival with
MAP between 55–60 mm Hg during active bleeding.
10
The European guideline on management of major bleeding and coagulopathy following
trauma recommends permissive hypotension with a systolic blood pressure target of
80–90 mm Hg (MAP 50–60 mm Hg) until major bleeding has been controlled (Recommendation
Grade 1C).
12
11.2.4
Aggressive approach and adverse outcomes
During hemorrhagic shock the endothelial glycocalyx becomes thinner and administration
of large amounts of crystalloids exacerbates this state, leading to fluid extravasation
that may cause cerebral, cardiac, and pulmonary edema.
19
,
9
,
12
Third spacing may also lead to cardiac dysfunction, worsen hemodynamics, and decrease
kidney perfusion. Decreased kidney perfusion occurs because of an increase in intra‐abdominal
pressure, which can additionally result in abdominal compartment syndrome.
19
,
9
11.2.5
Evidence
Several studies in trauma patients have demonstrated that hypotensive resuscitation
is correlated with benefits to survival, with significantly lower PRBC and amounts
of fluid required; in addition, there is diminution in the occurrence of multiple
organ dysfunction and acute respiratory distress syndrome.
2
Although recent evidence is mostly from trauma studies, a cohort study of women with
PPH showed that the group that received lower amounts of fluids had fewer signs of
shock with less blood product requirements.
13
In addition, the study showed that increased fluid administration leads to decreased
concentrations of fibrinogen, hemoglobin, hematocrit, platelet count associated with
prolonged prothrombin time, and partial thromboplastin time.
13
The study also demonstrated that administration of >4 L of fluids is associated with
subsequent bleeding and adverse maternal outcomes.
14
11.2.6
Hemostatic resuscitation
Resuscitation in hemorrhage was classically focused only on the administration of
fluids and PRBC. The use of FFP, PLT, and cryoprecipitate was delayed until coagulopathy
was demonstrated in paraclinics.
7
Hemostatic resuscitation limits the use of crystalloids and involves early administration
of blood products (not only PRBC), making massive transfusion protocols the cornerstone
of resuscitation.
9
,
12
11.2.7
Transfusion ratios
In hemostatic resuscitation, PRBC, FFP, and PLT are applied in a 1:1:1 ratio due to
the resemblance with whole blood and because a “high ratio” is related to fewer complications
and better patient survival outcomes.
8
,
9
,
12
,
16
If PRBC is not available, then whole blood can be used instead in case of massive
hemorrhage.
The strongest evidence for massive transfusions comes from the Prospective, Observational,
Multicenter, Major Trauma Transfusion (PROMTT) and Pragmatic, Randomized, Optimal
Platelet and Plasma Ratios (PROPPR) trials. The PROMTT study evidenced an improvement
in mortality in the first 6 h for patients with high ratios of transfusion (<1:2 vs
≥1:1).
16
Moreover, a secondary analysis from PROMTT revealed that early administration of plasma
(first 3 h and within the first 3–6 transfused units) was related to a decrease in
mortality at 24 h and 30 days.
17
However, the PROPPR study demonstrated that patients transfused with a 1:1:1 ratio
achieved hemostasis and suffered fewer deaths due to exsanguination at 24 h.
18
11.2.8
Fibrinogen and cryoprecipitate
In hemorrhages, fibrinogen is the first clotting factor to diminish its concentrations
to critical levels, with values of <200 mg/dl considered an indication for component
replacement.
9
,
12
Achieving specific fibrinogen levels is an important target during massive transfusion
(at least 150–200 mg/dl in PPH).
7
Sources for fibrinogen replacement are FFP, cryoprecipitate, and fibrinogen concentrates
(which are not widely available). Because fibrinogen concentration in FFP is variable
and relatively low, and its administration may dilute the existent fibrinogen, most
fibrinogen replacement is done with cryoprecipitate.
12
A unit of cryoprecipitate contains 2 g fibrinogen for each 100 ml; thus, a unit of
cryoprecipitate will increase serum fibrinogen by 10 mg/dl.
7
The usual dose of cryoprecipitate is 10 units, which is estimated to raise serum fibrinogen
by 100 mg/dl.
7
Subsequent doses must be adjusted conforming to serum fibrinogen levels.
11.2.9
Massive transfusion protocols
As the underlying physiological imbalance and clinical course in trauma seem similar
to severe PPH, massive transfusion protocols with high ratios utilized for trauma
may be useful for PPH.
20
,
21
Recommendations for ratios 1:1–1:2 for transfusions are different from previously
proposed protocols with ratios of 6:4:1 or 4:4:1, as in the CMQCC Obstetric Hemorrhage
Toolkit and from other obstetrics societies.
21
ACOG recommends administration of blood products in 1:1:1 ratio, mimicking whole blood
replacement.
22
Massive transfusion means requirements of ≥4 PRBC units (some articles considered
≥10 PRBC within 24 h), replacement of total blood volume within 24 h, or replacement
of 50% of blood volume within 3 h.
10
The protocol for massive transfusion is specific at each institution, but some schemes
have been suggested in the literature.
Once the massive transfusion protocol has been activated, the blood bank will send
blood products in rounds to the operating or labor room. Each round has a specific
number of PRBC, FFP, PLT, and cryoprecipitate units according to the protocol established
in the institution.
Typical rounds consist of 6 units PRBC, 6 units FFP, 6 units PLT or 1 platelet apheresis,
and 10 units of cryoprecipitate (Table 10).
9
,
24
,
25
Unless inactivated, the blood bank will prepare and send the products for rounds 2–4 successively,
and if the patient continues bleeding the protocol will start again from round 1.
7
TABLE 10
Massive transfusion protocol in obstetricsa
PRBCs
FFP
Platelets
Cryoprecipitate
Round 1
6 U
6 U
6 U
10 U
Round 2
6 U
6 U
6 U
10 U
Round 3
Tranexamic acid 1 g intravenously over 10 min
Round 4
6 U
6 U
6 U
aSource: Pacheco et al. [7].
John Wiley & Sons, Ltd
It is very important to notify the blood bank as soon as the transfusion requirements
decrease to stop the preparation of blood products.
7
11.2.10
Adverse outcomes
Although early transfusions are lifesaving and in theory help to achieve hemostasis
faster, thereby decreasing the number of blood products administered, the application
of multiple units of blood products could be associated with a higher incidence of
transfusion‐related complications. These complications include hyperkalemia, hypocalcemia,
citrate toxicity, transfusion‐related immunomodulation, transfusion‐related circulatory
overload (TACO), transfusion‐related kidney injury, transfusion‐related acute lung
injury (TRALI) (0.1 per 1000 units transfused), transfusion‐related febrile nonhemolytic
reactions (0.8 per 1000 units transfused), and acute hemolytic transfusion reaction
(0.19 per 1000 units transfused).
18
,
23
,
25
Transfusion‐related infectious diseases are uncommon (less than 1/100 000–1 000 000).,
18
,
23
BOX 15
FIGO recommends that all obstetricians are familiar with resuscitative measures in
the context of PPH including massive transfusion protocols.
REFERENCES
18
American College of Obstetricians and Gynecologists
. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician‐Gynecologists
Number 76, October 2006: postpartum hemorrhage. Obstet Gynecol. 2006;108:1039–1047.17012482
19
Owattanapanich
N
,
Chittawatanarat
K
,
Benyakorn
T
,
Sirikun
J
. Risks and benefits of hypotensive resuscitation in patients with traumatic hemorrhagic
shock: a meta‐analysis. Scand J Trauma Resusc Emerg Med. 2018;26:107.30558650
3
Cannon
JW
. Hemorrhagic shock. N Engl J Med. 2018;378:370–379.29365303
4
Wang
H
,
Chen
MB
,
Zheng
XW
,
Zheng
QH
. Effectiveness and safety of hypotensive resuscitation in traumatic hemorrhagic shock:
a protocol for meta‐analysis. Medicine. 2019;98:e18145.31770252
5
Carrick
MM
,
Leonard
J
,
Slone
DS
,
Mains
CW
,
Bar‐Or
D
. Hypotensive resuscitation among trauma patients. Biomed Res Int. 2016;2016:8901938.27595109
6
Johansson
PI
,
Oliveri
RS
,
Ostrowski
SR
. Hemostatic resuscitation with plasma and platelets in trauma. J Emerg Trauma Shock.
2012;5:120–125.22787340
7
Pacheco
LD
,
Saade
GR
,
Costantine
MM
,
Clark
SL
,
Hankins
GD
. An update on the use of massive transfusion protocols in obstetrics. Am J Obstet
Gynecol. 2016;214:340–344.26348379
8
Zwinkels
RLJ
,
Endeman
H
,
Hoeks
SE
,
de Maat
MPM
,
den Hartog
D
,
Stolker
RJ
. The clinical effect of hemostatic resuscitation in traumatic hemorrhage; a before‐after
study. J Crit Care. 2020;56:288–293.31917070
9
Spinella
PC
,
Pidcoke
HF
,
Strandenes
G
, et al. Whole blood for hemostatic resuscitation of major bleeding. Transfusion.
2016;56(Suppl 2):S190–202.27100756
10
Carvajal
JA
,
Ramos
I
,
Kusanovic
JP
,
Escobar
MF
. Damage‐control resuscitation in obstetrics. J Matern Fetal Neonatal Med. 2022;35:785–798.32102586
11
Bouglé
A
,
Harrois
A
,
Duranteau
J
. Resuscitative strategies in traumatic hemorrhagic shock. Ann Intensive Care. 2013;3:1.23311726
12
Spahn
DR
,
Bouillon
B
,
Cerny
V
, et al. The European guideline on management of major bleeding and coagulopathy following
trauma. Crit Care. 2019;23:98.30917843
13
Gillissen
A
,
van den Akker
T
,
Caram‐Deelder
C
, et al. Association between fluid management and dilutional coagulopathy in severe
postpartum haemorrhage: a nationwide retrospective cohort study. BMC Pregnancy Childbirth.
2018;18:398.30305108
14
Henriquez
DDCA
,
Bloemenkamp
KWM
,
Loeff
RM
, et al. Fluid resuscitation during persistent postpartum haemorrhage and maternal
outcome: a nationwide cohort study. Eur J Obstet Gynecol Reprod Biol. 2019;235:49–56.30784827
15
Pham
HP
,
Shaz
BH
. Update on massive transfusion. Br J Anaesth. 2013;111(Suppl 1):i71–82.24335401
16
Holcomb
JB
,
del Junco
DJ
,
Fox
EE
, et al. The prospective, observational, multicenter, major trauma transfusion (PROMMTT)
study: comparative effectiveness of a time‐varying treatment with competing risks.
JAMA Surg. 2013;148:127–136.23560283
17
del Junco
DJ
,
Holcomb
JB
,
Fox
EE
, et al. Resuscitate early with plasma and platelets or balance blood products gradually:
findings from the PROMMTT study. J Trauma Acute Care Surg. 2013;75(1 Suppl 1):S24–30.23778507
18
Holcomb
JB
,
Tilley
BC
,
Baraniuk
S
, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2
ratio and mortality in patients with severe trauma: the PROPPR randomized clinical
trial. JAMA. 2015;313:471–482.25647203
19
Tanaka
H
,
Matsunaga
S
,
Yamashita
T
, et al. A systematic review of massive transfusion protocol in obstetrics. Taiwan
J Obstet Gynecol. 2017;56:715–718.29241907
20
Clark
SL
,
Hankins
GD
. Preventing maternal death: 10 clinical diamonds. Obstet Gynecol. 2012;119(2 Pt 1):360–364.22270288
21
Bingham
D
,
Melsop
K
,
Main
E
. CMQCC Obstetric Hemorrhage Toolkit Hospital Level Implementation Guide. The California
Maternal Quality Care Collaborative (CMQCC). Stanford University School of Medicine;
2010.
22
Committee on Practice Bulletins‐Obstetrics
. Practice bulletin no. 183: postpartum hemorrhage. Obstet Gynecol. 2017;130:e168–e186.28937571
23
Pacheco
LD
,
Saade
GR
,
Costantine
MM
,
Clark
SL
,
Hankins
GD
. The role of massive transfusion protocols in obstetrics. Am J Perinatol. 2013;30:1–4.22836824
24
Kogutt
BK
,
Vaught
AJ
. Postpartum hemorrhage: Blood product management and massive transfusion. Semin Perinatol.
2019;43:44–50.30527516
25
Vasudev
R
,
Sawhney
V
,
Dogra
M
,
Raina
TR
. Transfusion‐related adverse reactions: from institutional hemovigilance effort to
National Hemovigilance program. Asian J Transfus Sci. 2016;10:31–36.27011667
12
KEY STATEMENTS
Care bundles have been associated with improved patient outcomes when adherence is
high. The goal of the PPH bundle is to reduce the frequency of severe hemorrhage and
improve maternal outcomes. There is still a need for good‐quality research to determine
whether the bundle approach will ultimately make a difference in saving women's lives
from PPH.
In recent years, new scientific evidence and the availability of new technologies
have driven important reflections about PPH. To guarantee quality of guidelines it
is important to update the evidence and base recommendations on the best quality studies
available. It is also essential to stimulate production of new research on the key
themes of PPH to reduce disparities among guidelines. PPH guidelines have helped improve
the care of women around the world and their use should be stimulated in all scenarios.
The shock index indicator, defined as the ratio of heart rate to systolic blood pressure,
is simple to use. It has better predictive ability than other vital signs because
it detects acute changes in the maternal cardiovascular system and appears as an early
marker to predict adverse outcomes.
Evidence continues to support oxytocin as the first‐line drug in the prevention of
PPH in all births.
Women with PPH should receive a fixed dose of 1 g tranexamic acid in 10 ml (100 mg/ml)
intravenously (1 ml/min) as soon as possible after delivery and no more than 3 h after
birth. A second dose of 1 g should be given intravenously if bleeding continues after
30 min or restarts within 24 h of the first dose. Tranexamic acid should be given
in addition to usual treatments for the management of PPH including medical (uterotonics),
nonsurgical, and surgical interventions, regardless of the cause of hemorrhage or
the mode of delivery.
The nonpneumatic antishock garment (NASG) is an effective nonsurgical device that
should be in every healthcare facility. The NASG, when used as a temporizing measure
to recover hemodynamic stability in the context of PPH, decreases morbidity, mortality,
and hypovolemic shock, and is of special importance in LMICs. While considerable research
is still necessary to improve knowledge on implementation issues, professional associations
and national and international guidelines should continue to encourage NASG use for
refractory PPH management.
Uterine balloon tamponade (UBT) is an effective nonsurgical technique that when employed
rapidly by a properly trained person with a proven device in the context of quality
PPH care (the PPH bundle) improves survival of women with refractory PPH. National
and international guidelines should include UBT use in the management of PPH.
Interventional radiology may be indicated for the prevention and treatment of PPH
either before delivery, in cases of known placental abnormalities and implantation,
or after delivery when the patient is hemorrhaging. Prophylactic catheterization of
the uterine arteries, with embolization, can be considered an important therapeutic
strategy that is safe and effective for reducing maternal and fetal morbidity and
mortality by controlling blood loss.
Regardless of the compression suture chosen, obstetricians must first quickly recognize
the onset of PPH, safely administer uterotonics, and place emergent compression sutures
if needed. In the immediate postoperative period, women should be monitored for complications
such as hematometra, pyometra, and uterine synechiae. Most important is the ability
of the obstetrician to control bleeding using medical and surgical interventions,
stabilize the mother, and reduce maternal morbidity.
PPH is a serious life‐threatening obstetric emergency and early recognition of this
condition results in better outcomes. In cases where medical treatment fails to control
the bleeding, several surgical options exist. To date, no randomized controlled trials
have assessed these techniques, nor compared the superiority of one to another, and
all the data are based on case reports and case series. Moreover, the use of these
methods largely depends on the facilities provided in each institution and on the
care providers’ skills and familiarity with the procedures. Hence, an effort should
be exercised for better training of all care providers in these life‐saving techniques.
Future fertility rate following these procedures remains underassessed due to the
lack of long‐term follow‐up for these cases. In the future, more research should target
these surgical techniques to shy away from the more morbid procedures, thereby improving
maternal and perinatal outcomes.
Damage control resuscitation (DCS) is a combination of resuscitation and surgical
interventions with the purpose of restoring hemostasis and normal physiology. These
techniques have proven to be applicable in obstetrics, with satisfactory results controlling
refractory PPH and an overall decreased mortality of critically ill patients, especially
in patients in whom conventional treatment can be linked to a high risk of failure.
DCS is an available therapeutic approach for the management of severe PPH, thus proper
training must be widespread to implement this technique.
Basic recommendations for resuscitation in PPH include administration of crystalloids
in small boluses of 500 ml, checking clinical signs and looking for its improvement,
and use of balanced crystalloid solutions such as Ringer's lactate, which is preferred
over chlorine‐rich solutions. The target blood pressure in hypotensive resuscitation
is 80–90 mm Hg for systolic blood pressure or 50–60 mm Hg for mean blood pressure.
In hemostatic reanimation, fewer crystalloids are administered and, instead, transfusional
replacement is started earlier with high ratios of transfusion (1:1:1). During massive
transfusions, the target for serum fibrinogen is 150–200 mg/dl and the usual dose
of cryoprecipitate is 10 units; it is estimated that these will raise the serum fibrinogen
by 100 mg/dl. The protocol for massive transfusion is specific at each institution.
Physicians should be familiar with their hospitals’ protocol and recommendations.
Anyone who attends a birth can be taught simple home‐based life‐saving skills. The
evidence‐based prevention and management of PPH can be achieved with the use of relatively
inexpensive drugs. Women should be monitored closely during the first hour after delivery
of the baby and placenta, and accurate blood loss measurement should be implemented.
Barriers and gaps can be addressed through providing an enabling environment through
supportive policies, designing a formal plan for supplies, task shifting strategies,
and use of guidelines and protocols for successful implementation.
Simulation training on how to manage PPH is encouraged, and each hospital should have
a protocol on the management of PPH. OBGYN societies should lobby to have the essential
medications that are needed to prevent and treat PPH readily available in all maternity
centers.
13
IMPLEMENTATION OF THE FIGO RECOMMENDATIONS BY HEALTH SYSTEMS AND NATIONAL SOCIETIES
FOR THE MANAGEMENT OF POSTPARTUM HEMORRHAGE
FIGO must lobby and work with other international organizations to reduce maternal
mortality and morbidity due to PPH.
FIGO recommends that all national societies work in collaboration with nurses and
midwives to lobby with their respective regional and national organizations to promote
and implement these recommendations.
All OBGYN societies in conjunction with other healthcare societies must endorse a
strategy for effective prevention and treatment of PPH.
All national societies must lobby with their local national governments to establish
a PPH bundle approach and make the medical supplies and surgical equipment needed
for the management of PPH readily available in all regions of their countries.
All health systems are obligated to provide respectful care of the woman, the infant,
and the associated family. Health systems must provide the appropriate and effective
medications, water, oxygen, equipment, training, and transfer mechanisms to save the
lives of women and newborns.
MEMBERS OF THE FIGO SAFE MOTHERHOOD AND NEWBORN HEALTH COMMITTEE, 2018–2021
Anwar H. Nassar (Chair), Gerard H. Visser (Past Chair), Eytan R. Barnea, Maria Fernanda
Escobar, Yoon Ha Kim, Wanda Kay Nicholson, Rodolfo Pacagnella, Diana Ramasauskaite,
Gerhard Theron, Alison Wright.